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Introduction
Patients with cardiac diseases or conditions with high risk of develop-
ing cardiac diseases undergo risk assessment by cardiologists, primary
care physicians, and scientists based on referral for more advanced
risk assessment strategies, institution of preventive treatments,
counselling of patients and their relatives, and selection of patients
for scientific trials. The various methods used for risk assessment dif-
fer with respect to availability, complexity, and usefulness in different
patient populations. Parameters associated with increased risk of e.g.
death may also be associated with higher risk of other adverse out-
comes. However, risk assessment strategies including specific meth-
ods for risk assessment and risk scores should be used only for the
purposes for which they are validated.
This expert consensus statement of the European Heart Rhythm
Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart
Rhythm Society (APHRS), and the Latin American Heart Rhythm
Society (LAHRS) summarizes the consensus of the international writ-
ing group based on a thorough review of the medical literature re-
garding risk assessment in cardiac arrhythmias. To create a tool for
clinicians to perform rational and evidence-based risk stratification,
this task force was set down by EHRA, HRS, LAHRS, and APHRS, in-
cluding representatives from each of the four societies.
With this document, we intend to describe and review status of
performing risk assessment in different patient populations with car-
diac diseases or conditions with high risk of developing such. Our
objectives are to raise awareness of using the right risk assessment
tool for a given outcome in a given population, and to provide physi-
cians with practical proposals that may lead to improvement of pa-
tient care in this regard. For quick reference, sub-chapters start with
a short section on consensus statements. The document concludes
with a summary of consensus statements.
Evidence review
Members of the Task Force were asked to perform a detailed litera-
ture review using PubMed and EMBASE, weigh the strength of evi-
dence for or against a particular treatment or procedure, and include
estimates of expected health outcomes for which data exist. Patient-
specific modifiers, comorbidities, and issues of patient preference
that might influence the choice of particular tests are considered, as
are frequency of follow-up and cost-effectiveness. In controversial
areas, or with regard to issues without evidence other than usual clin-
ical practice, consensus was achieved by agreement of the expert
panel after thorough deliberations. This document was prepared by
the Task Force and peer-reviewed by official external reviewers rep-
resenting EHRA, HRS, APHRS, and LAHRS.
Consensus statements are evidence-based and derived primarily
from published data or determined through consensus opinion if no
data available. Current systems of ranking level of evidence are be-
coming complicated in a way that might compromise their practical
utility.1 In contrast to guidelines, we opted for an easier user-friendly
system of ranking using ‘coloured hearts’ that should allow physicians
to easily assess the current status of the evidence and consequent
guidance (Table 1). This EHRA grading of consensus statements does
not have separate definitions of the level of evidence. The categoriza-
tion used for consensus statements must not be considered directly
similar to the one used for official society guideline recommendations
which apply a classification (Class I–III) and level of evidence (A, B,
and C) to recommendations used in official guidelines.
Thus, a green heart indicates a ‘should do this’ consensus statement
or indicated risk assessment strategy based on at least one randomized
trial or supported by strong observational evidence that it is beneficial
and effective. A yellow heart indicates general agreement and/or scien-
tific evidence favouring a ‘may do this’ statement or the usefulness/effi-
cacy of a risk assessment strategy or procedure. A ‘yellow heart’
symbol may be supported by randomized trials based on a small num-
ber of patients or not widely applicable. Risk assessment strategies for
which there is scientific evidence of no benefit or potential harm and
should not be used (‘do not do this’) are indicated by a red heart.
Finally, this consensus document includes evidence and expert
opinions from several countries. The risk assessment approaches dis-
cussed may therefore include tests not approved by governmental
regulatory agencies in all countries.
Relationships with industry and other
conflicts
All members of the writing group, as well as reviewers, have disclosed
any potential conflicts of interest. Details are available in
Supplementary material online.
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All consensus statements were voted upon by the writing commit-
tee independently and reached the predefined level of >_75% consen-
sus for inclusion in consensus statement tables. Each partner society
officially reviewed the document, and all reviewer comments were
addressed. Each partner society approved the final document and
consensus statements.
General tools for risk assessment,
strengths, limitations, and pretest
probability
Value of clinical history and
characteristics including clinical risk
scores such as CHA2DS2-VASc
Clinical assessment of the patient with cardiac arrhythmias starts with a
good clinical history and basic investigations for an underlying aetiologi-
cal factor for the arrhythmia or its associated complication(s). In addi-
tion, an assessment of the risks and benefits of any therapeutic
intervention should be made, and appropriate management initiated.
Following on from clinical history and assessment, there is a pro-
posal toward a more integrated and holistic approach to arrhythmia
management, as evident in guidelines. Such an integrated approach
requires multidisciplinary teams of healthcare professionals, patient
involvement, access to treatment options, and decision-support tools
to optimize the patient journey. Many proposals have been made to-
wards the operationalization of such an integrated approach to risk
assessment and practical management in cardiac arrhythmias, which
has been of varying complexity. As an example, the management of
atrial fibrillation (AF) has been simplified into the ABC pathway (‘A’
Avoid stroke with Anticoagulation; ‘B’ Better symptom management,
with patient-centred and symptom-directed decisions on rate or
rhythm control; ‘C’ Cardiovascular and comorbidity risk manage-
ment), which has been shown to be associated with improved clinical
outcomes and reduced healthcare costs.2–6
This makes a strong argument for using the right approaches and
clinical tools for patient assessment, but using them appropriately for
the reasons they were first proposed (e.g. stroke risk scores to assess
stroke risk, and not other outcomes).
Taking AF as an illustrative example with regard to using the right
score for the right reason there are many risk factors for stroke (but
the more common and validated ones have been used to formulate
risk stratification tools).7 The most common in use is the CHA2DS2-
VASc score8 but it is not meant to include every possible stroke risk
factor, and was designed to be simple, reductionist and practical to
help decision-making for stroke risk. As with all clinical scores based
on clinical factors, the CHA2DS2-VASc score only performs mod-
estly for predicting high-risk patients who sustain events. The use of
more clinical factors and biomarkers improves prediction (at least
statistically) but the practical added value is marginal, and less impres-
sive in real-world cohorts.9,10 Use of simplified scores to artificially
categorize patients into low-, moderate- and high-risk strata can be
problematic, as in the real-world patients do not necessarily fall into
three neat categories of risk. Also, not all risk factors carry equal
weight, hence, the move to focus the initial decision-making on identi-
fying low-risk patients who do not need antithrombotic therapy first,
following which stroke prevention can be offered to AF patients with
>_1 stroke risk factors.9 Stroke risk is also highly dynamic, and al-
though logistically challenging, a clinical reassessment may be needed
every 4–6 months to optimize risk re-assessment.11–13 As the
CHA2DS2-VASc is a cluster of common cardiovascular risk factors, it
is predictive of death, cardiovascular hospitalizations, and other ad-
verse outcomes that the CHA2DS2-VASc score was not designed
for. Also, given that many components of the CHA2DS2-VASc score
are associated with incident AF, the CHA2DS2-VASc score is used to
predict new onset AF, again something it was not designed for.
Another misuse of the CHA2DS2-VASc score is the prediction of
bleeding risk. Nevertheless, formal comparisons show that the
CHA2DS2-VASc (and older CHA2DS2) score are inferior to a formal
bleeding risk score such as the HAS-BLED score, for the prediction
of major bleeding in AF patients.14
Indeed, bleeding risk is also highly dynamic, and the appropriate
use of bleeding risk scores such as HAS-BLED is to address modifi-
able bleeding risk factors (e.g. uncontrolled hypertension, labile INR,
concomitant aspirin, or NSAID use) then to schedule the ‘high risk’
patients for early and more frequent follow-up visits (e.g. 4 weeks
rather than 4 months).15 Only focusing on modifiable bleeding risk
factors is an inferior strategy for bleeding risk assessment, compared
to the HAS-BLED score.8
We should use the scores only for the purposes they were
designed for. Attention to appropriate methodology, statistics, etc.—
as well as other clinical states merits consideration e.g. sudden death
.................................................................................................
Table 1 Scientific rationale of consensus statements
Definitions related to a
treatment or procedure
Consensus
statement
instruction
Symbol
Scientific evidence that a treat-
ment or procedure is benefi-
cial and effective. Requires at
least one randomized trial, or
is supported by strong obser-
vational evidence and authors’
consensus (as indicated by an
asterisk).
‘Should do this’
General agreement and/or scien-
tific evidence favour the use-
fulness/efficacy of a treatment
or procedure. May be sup-
ported by randomized trials
based on a small number of
patients or not widely
applicable.
‘May do this’
Scientific evidence or general
agreement not to use or rec-
ommend a treatment or
procedure.
‘Do not do this’
The categorization for our consensus document should not be considered directly similar
to the one used for official society guideline recommendations which apply a classification
(I–III) and level of evidence (A, B, and C) to recommendations.
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prediction (or failed ablation, device infection, etc.), Charlson
Comorbidity Index, frailty etc.—but using the right score designed
for that purpose.
If appropriately used, some of these (simplified) tools help with
clinical management. Indeed, the value of a medical test is measured
by its accuracy as well as how it impacts medical decisions and ulti-
mately patient health. As medical tests are considered and new ones
emerge, they should be considered and evaluated in a framework of
accuracy and patient impact.16 A test must not only be accurate, but
also feasible. Tests that are difficult to reproduce, subject to technical
failures, or difficult to interpret are likely to impact patient care as a
consequence of a primary failure to produce a definitive and action-
able result.
Electrocardiographic methods including
monitoring
Electrocardiographic methods
The ECG is the gold standard for risk assessment in patients with or
at risk of developing cardiac arrhythmias. The 12-lead ECG is inex-
pensive and widely available. Risk stratification with the ECG is lim-
ited in general by its low positive predictive value (PPV) determined
to a large extent by the low prevalence of cardiovascular events in
the general population. However, the prognostic significance of the
ECG is enhanced in patients with heart disease.
P wave and PR interval
The prognostic value of P wave characteristics has been examined in
subjects enrolled in clinical trials of AF for prediction of the
development of AF, where maximum P wave duration was a signifi-
cant independent risk marker for the development of AF over
10 years.20 This observation was confirmed by epidemiologic/popula-
tion studies (including ARIC and the Copenhagen ECG studies) that
showed increased risk of AF in patients with prolonged P wave dura-
tion and PR interval prolongation,21–23 and summarized in a review
by Nikolaidou et al.24 Moreover, a prolonged P wave duration was
determined as a sensitive predictor of post-operative AF in patients
undergoing coronary artery bypass grafting (CABG).25 The definition
of an abnormal P wave varies greatly depending on how it is mea-
sured, and definitions vary depending on whether P wave area, dura-
tion, terminal forces in lead V1 or signal-averaged P wave are
analysed. Abnormal P wave morphology was associated with incident
stroke in the Multi-Ethnic Study of Atherosclerosis.26 The prognostic
significance of PR interval prolongation, which is variably defined as
PR intervals greater than 196–220 ms, is controversial and depends
on the patient population studied. Most studies show that PR interval
prolongation is not associated with increased mortality in healthy
middle-aged individuals during medium term follow-up. On the other
hand, a number of reports show worse survival in patients with sus-
pected heart failure (acute and chronic) or heart disease [coronary
artery disease (CAD)]. Additionally, PR prolongation and P wave
prolongation predict increased risk of AF and the greater degrees of
PR prolongation and P wave duration predicted higher risks of
AF.27,28 An increased PR interval is also associated with poor cardio-
vascular outcomes in patients with AF.29 Several studies have shown
that PR prolongation in patients undergoing cardiac pacing or receiv-
ing cardiac resynchronization therapy (CRT) is an independent
....................................................................................................................................................................................................................
Electrocardiographic methods including monitoring Class References
Twelve-lead electrocardiogram (ECG) should be obtained in all patients undergoing evaluation
for known or suspected heart disease.
17
The 12-lead ECG provides diagnostic and prognostic information in patients with inherited high-
risk syndromes including long QT syndrome (LQTS), short QT syndrome, Brugada Syndrome,
and arrhythmogenic cardiomyopathy (ACM) and should be obtained.
17
Exercise ECG provides diagnostic and prognostic information for patients with LQTS ACM, hy-
pertrophic cardiomyopathy (HCM), catecholaminergic polymorphic ventricular tachycardia,
and documented or suspected arrhythmias related to exertion, and should be obtained.
17
Ambulatory ECG evidence of non-sustained ventricular tachycardia provides prognostic informa-
tion in ischaemic cardiomyopathy, ACM, and HCM and should be obtained.
17
The signal-averaged ECG and QRS fragmentation may aid in the diagnosis of ACM. 18
The signal-averaged ECG and QRS fragmentation may be useful in risk stratification of Brugada
syndrome.
18
Heart rate variability, heart rate turbulence, signal-averaged ECG, and T wave alternans analysis,
when used in combination with additional clinical, electrocardiographic, and structural meas-
ures, may be useful for identifying high- and low-risk groups among patients with acquired
structural heart disease.
19
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predictor of worse prognosis and lower probability of reverse
remodelling as well as an increased risk of AF, death, and hospitaliza-
tion.30,31 There are no data indicating whether the degree of PR pro-
longation portends a worse outcome compared to patients who
have lesser degrees of PR prolongation, nor is there information on
its prognostic value in acute inferior wall myocardial infarction (MI).
QRS, QT interval, and T-wave
Over the years, a number of ECG techniques have been developed
to assess risk of ventricular tachyarrhythmias (VTs). These have the
advantage of being non-invasive and, often, inexpensive. For almost
all of these techniques, there are conflicting data, and not one tech-
nique has proven beneficial in patients with structural heart disease.
Moreover, studies have varied in their reporting of sudden arrhyth-
mic death vs. total mortality. Among the risk predictors shown to
have value are QRS widening and fragmentation, QT prolongation,
T-wave abnormalities, and ventricular ectopy. Although the prognos-
tic value of each ECG parameter in isolation is limited, in combination
with additional ECG, imaging, and genetic testing, these parameters
can contribute to effective risk stratification.
QRS
QRS prolongation has been associated with all-cause mortality in
heart failure patients, implantable cardioverter-defibrillator (ICD)
shocks, and inducibility of sustained VT. QRS prolongation in patients
on Class IC antiarrhythmic drugs is a predictor of pro-arrhythmia,
and should be monitored, particularly during exercise. QRS prolon-
gation predicts risk in patients with myotonic dystrophy and in
Brugada Syndrome. Additional prognostic information from the QRS
is obtained from the signal-averaged ECG, which amplifies the QRS,
averages multiple complexes to reduce noise, and filters out the T-
wave in order to detect late potentials, and provides evidence of
slow conduction substrate that associates with risk of re-entry
tachyarrhythmias.17 The signal-averaged ECG has been used to de-
tect risk of ventricular arrhythmias in post-infarction patients, ACM,
and Brugada Syndrome. Although its specificity is limited, its negative
predictive value is high, particularly in survivors of inferior wall myo-
cardial infarction. The signal-averaged ECG is not useful in patients
with underlying bundle branch block. QRS fragmentation, which
includes abnormally notched narrow and wide QRS complexes, is as-
sociated with the presence of myocardial scar and is also associated
with mortality in patients with cardiomyopathy and with Brugada
Syndrome.32 The presence of an unprovoked type 1 Brugada
Syndrome pattern is associated with increased risk as is discussed
later in the document.
QT interval
Measurement of the QT interval can be complicated by QRS prolon-
gation and by the need to correct for heart rate, as has been de-
scribed elsewhere.33 Despite these limitations, prolongation of the
heart rate-corrected QT interval (QTc) has been associated with
mortality in several population studies.34,35 In congenital long QT syn-
drome (LQTS), the length of the QT interval is a major predictor of
risk of cardiac events, including sudden cardiac death (SCD). When
initiating QT-prolonging drugs such as sotalol or dofetilide, a QT
interval of 500 ms or higher should prompt reduction or discontinua-
tion of the offending drug(s).
QT dispersion
This measure of ventricular repolarization heterogeneity is typically
defined from the 12-lead ECG as the QTmax  QTmin. It has been
used to predict a wide variety of events, including ventricular pro-
arrhythmia, VTs, although the sensitivity, specificity, and accuracy are
poorly defined and highly dependent on the patient population
studied.36
T wave
T wave inversions are common and may be non-specific or may signal
important abnormalities such as ischaemia or hypertrophy.
Widespread deep T wave inversions in combination with QT prolon-
gation, such as may occur in acute stress cardiomyopathy, can be as-
sociated with torsades de pointes. Abnormal T wave notching can be
a clue to abnormal repolarization and is often seen in patients with
QT prolongation. Computerized T-wave analytic techniques such as
principal component analysis, T-wave residuum, flatness, asymmetry,
and notching have been developed in an effort to detect and quantify
abnormal repolarization and may have particular value in identifying
patients with LQTS.37,38 Moreover, it has been shown that adding T-
wave morphology characterizations to age, gender, and QTc in a sup-
port vector machine model can improve LQTS diagnosis.39
However, these additional analytic techniques are not used in routine
clinical practice.
The Tpeak-end interval, measured from the peak to the end of the
T-wave, thought to reflect heterogeneity of repolarization in the
heart, has been associated with arrhythmic risk in various popula-
tions.40 However, considerable controversy remains as to how it
should be measured and applied.41
T-wave alternans is a beat-to-beat alternation of T wave morphol-
ogy. When seen with the naked eye, it usually accompanies marked
QT prolongation and is a harbinger of imminent torsades de pointes.
Analysis of more subtle T-wave alternans has been used for assessing
abnormal and heterogeneous repolarization to predict mortality and
arrhythmic risk. Abnormal microvolt T-wave alternans assessed using
the spectral method during graded exercise has a high negative pre-
dictive value and has been used to identify a subgroup of patients
with reduced ejection fraction who are not likely to benefit from defi-
brillator implantation.18 Microvolt T-wave alternans analysis cannot
be performed when the rhythm is AF, and patients with ventricular
pacing have not been studied extensively.
Early repolarization
Early repolarization pattern, highly prevalent in the overall popula-
tion, defined as an elevation of the J point of at least 0.1 mV, may oc-
cur in the anteroseptal or inferolateral leads. In 2008, Haissaguerre
reported an association of inferolateral early repolarization with in-
creased risk of idiopathic ventricular fibrillation (VF) in a case–control
study42 and subsequently confirmed in other case–control studies.
Exercise testing or isoproterenol testing improved the pattern of
repolarization, and the pattern was accentuated with exposure to
beta-adrenergic blockers. In a meta-analysis of population-based
studies, inferolateral early repolarization was associated with
increased risk of arrhythmic death, but the risk was still quite low in
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general (70/100 000 patient-years).43 It appears that individuals at
highest risk have early repolarization in multiple (especially inferior)
leads, with high voltage (at least 0.2 mV), and with notching or
horizontal/down-sloping ST segments. Early repolarization is espe-
cially prevalent in young men, particularly young black men, and in
athletes.44 Because the absolute risk of arrhythmic death is so low,
asymptomatic individuals with early repolarization, even those with
higher risk ECG patterns, do not require further evaluation except
when there is a strong family history of sudden cardiac death or
when the J point elevation is associated with Brugada syndrome (dis-
cussed later in this document) or short QT syndrome (SQT).
Ambulatory electrocardiographic monitoring
In 1984, Bigger et al. showed that ventricular ectopy recorded on a
Holter monitor, especially when combined with a low left ventricular
ejection fraction (LVEF), predicted a higher risk of mortality in post-
infarction patients compared to those without ectopy.45 Non-
sustained VT is also associated with increased risk in patients with
arrhythmogenic and hypertrophic cardiomyopathy (HCM). Other
data that can be extracted from ambulatory monitoring include heart
rate, heart rate variability, and heart rate turbulence measurements,
which can predict mortality risk at least in ischaemic cardiomyopathy
(ICM), but have not been incorporated into clinical practice.19,46
Imaging
Risk assessment of ventricular tachyarrhythmia using
imaging modalities
Evaluation for the presence of structural heart disease (SHD) is im-
portant for patients suspected of being at risk for sudden cardiac
death. Left ventricular ejection fraction remains the key independent
parameter for risk stratification of sudden cardiac death and to guide
implantation of an ICD.47,48 Randomized controlled trials have
shown a survival benefit from ICDs in patients with SHD and an EF
<_35%.54–56 Although EF is currently the only proven imaging modal-
ity demonstrated to risk stratify for sudden cardiac death, only 1–5%
of patients with ICDs, implanted based upon a low EF, require thera-
pies each year and the large majority of patients who receive ICDs
will not have ICD therapies over the 3-year period after implanta-
tion.57,58 In addition, up to 70% of all sudden cardiac deaths in the
community occur in individuals with EF >35%.58–60 Although the
Efficacy of ICDs in Patients with Non-ischaemic Systolic Heart Failure
(DANISH) trial showed that primary prevention ICD in the setting of
severe non-ICM did not reduce all-cause mortality in patients on op-
timal medical therapy for heart failure, ICD implantation was associ-
ated with a 50% reduction in arrhythmic death. Of note, within this
non-ICM population, younger patients (<68 years old) experienced a
mortality benefit of 36% if treated with an ICD.61
Ejection fraction is most readily evaluated with echocardiography
(recommendation level: green), given both lower cost, availability of
equipment, and available expertise; however, cardiac MRI or CT can
also be used to evaluate EF and SHD, particularly if obtained in com-
bination of other assessment aims, such as CAD or if there is contro-
versy over the quantified EF with echo (recommendation level:
green). The imaging modality used to estimate EF has not been
shown to determine benefit from ICD.48
Additional parameters beyond EF remain to be tested in large
studies. Cardiac MRI with late gadolinium enhancement (LGE) can
provide important prognostic information and may allow for more
accurate assessment of scar. Presence and location of scar can por-
tend a higher risk of sustained VT.49–51,62,63 In a study of 452 non-
ICM patients with New York Heart Association Class II or II and EF
<35%, ICD implantation was only associated with reduced mortality
in the population that had presence of scar on cardiac MRI.64 Cardiac
positron emission tomography (PET) may elucidate areas of
inflammation which may identify inflammatory cardiomyopathies and
sarcoidosis, a condition that is associated with higher risk of
ventricular arrhythmias in patients without CAD (increased F-2-
fluorodeoxyglucose uptake) or can be used to identify sympathetic
denervation (carbon-11-metahydroxyephedrine imaging) or regions
of inflammation. Greater sympathetic denervation on PET in a
prospective study of ICM patients was a better predictor of ICD
shocks than EF.65 Uptake of iodine-123 meta-iodobenzylguanidine
(MIBG) to evaluate heart to mediastinum ration (H/M ratio) has
shown mixed results in predicting arrhythmic death with some stud-
ies suggesting additional prognostic benefit for this parameter, while
others have not demonstrated additional value.66,67 Importantly, the
value of these additional parameters in determining risk of sustained
VT, VF, or benefit from ICD in various population remains to be clari-
fied. Finally, routine use of viability assessment using PET to guide re-
vascularization in order to reduce risk of SCD remains an area of
investigation. In patients with an EF <35% and CAD amenable to re-
vascularization, routine use of PET to guide revascularization was not
beneficial in reducing overall mortality.68
Imaging modalities for atrial arrhythmias
Echocardiography (transthoracic or transoesophageal) is a valuable
tool in patients who present with atrial arrhythmias, specifically atrial
flutter and AF, to evaluate for the presence of structural heart
.................................................................................................
Imaging (echo, computed tomog-
raphy (CT), magnetic resonance
imaging (MRI), perfusion)
Class References
Echocardiography should be used to
evaluate EF for risk assessment for
primary prevention of sudden cardiac
death and the presence of structural
heart disease. Alternatively, MRI or
cardiac CT can be used.
47,48
Cardiac MRI is useful in assessing aetiol-
ogy-driven risk of VT and for the
presence of scar or myocardial
inflammation.
49–51
Cardiac positron emission tomography
may be useful for the assessment of
aetiology-driven risk of ventricular
arrhythmias and the presence of scar
or myocardial inflammation in
patients without CAD.
52,53
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disease, left atrial enlargement, and valvular heart disease in order to
better define treatment options. Cardiac MRI or CT may also be
used if images obtained at echocardiography are not reliable.
However, routine use of echocardiography, including atrial strain or
atrial function in patients who do not have atrial arrhythmias to assess
risk for the development of AF or atrial flutter is not warranted, un-
less other structural cardiac abnormalities are suspected.
Invasive electrophysiological study
Currently, there are a few indications to perform an electrophysio-
logical study (EPS) to further assess the risk of arrhythmias in at-risk
cardiac patients. Such patients include those with structural heart dis-
ease, LVEF >35%, pre-syncope, syncope, palpitations, or markedly
abnormal ECG suggesting severe conduction disease. These patients
can be considered for an EPS to assess the risk of ventricular arrhyth-
mias and sudden cardiac death to decide on need of an ICD, or to
identify conduction disturbances or supraventricular tachycardias
that can be treated with ablation or pacing.70,71
Patients withICM without a primary indication for an ICD, EF
<_40%, and non-sustained VT on ambulatory cardiac monitoring are
candidates for an EPS according to the findings in the MUSTT trial,73
in which, 35% of patients with inducible sustained VT had a signifi-
cantly lower risk of death with an ICD.66 The MADIT trial initially
also utilized an EPS in post-MI patients with an EF <_30%, and non-
sustained VT events to implant an ICD, and showed survival benefit
with the ICD.54 However, MADIT-II subsequently eliminated the
need for an EPS in post-MI patients with an EF <_30% and similarly
showed the life-saving benefit of the ICD in a broader patient co-
hort.55 Therefore, post-MI patients with an EF <_30% do not currently
need to undergo an EPS to guide decisions on whether to implant an
ICD.
In patients with heart failure and EF <_ 35%, an EPS is not recom-
mended for risk assessment for the decision on ICD indication. Some
centres perform an EPS for inducibility to better characterize in-
duced, sustained VT events, and their response to anti-tachycardia
pacing, which may potentially help to tailor ICD programming.
Furthermore, in patients who have syncope of uncertain origin, an
....................................................................................................................................................................................................................
Invasive electrophysiological study (EPS) Class References
EPS is indicated in patients with syncope and previous myocardial infarction, or other
scar-related conditions when syncope remains unexplained after non-invasive
evaluation.
69
EPS may be considered in patients with syncope and asymptomatic sinus bradycardia,
in a few instances when non-invasive tests (e.g. ECG monitoring) have failed to
show a correlation between syncope and bradycardia
70–72
EPS may be considered in patients with EF <_ 40%, without a primary prophylactic
ICD indication, and non-sustained VT in ICM (MUSTT criteria) to ascertain the
presence of sustained VT events.
73
EPS may be helpful in patients with syncope and presence of a cardiac scar, including
those with a previous myocardial infarction, or other scar-related conditions, when
the mechanism of syncope remains unexplained after non-invasive evaluation.
66,70,71,73
EPS may be considered in patients with syncope and bifascicular block, when the
mechanism of syncope remains unexplained after non-invasive evaluation.
67,70,71,74
EPS may be considered for risk stratification of SCD in patients with tetralogy of
Fallot who have one or more risk factors among LV dysfunction, non-sustained VT
and QRS duration exceeding 180 ms.
67,70,71,74
EPS may be considered in patients with congenital heart disease and non-sustained
VT to determine the risk of sustained VT or identify SVT that could be ablate.
67,70,71,74
EPS may be considered in asymptomatic patients with spontaneous type 1 Brugada
ECG pattern, or drug-induced type 1 ECG pattern and additional risk factors.
75–77
EPS is not recommended for additional risk stratification in patients with either long
or short QT, catecholaminergic VT or early repolarization.
70,71
EPS is not recommended for risk stratification in patients with ischaemic or non-
ischaemic DCM who meet criteria for ICD implantation.
70,71
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EPS could identify ventricular arrhythmias or document electrical
conduction disorders.67,70,71,74
In the case of channelopathies, there is no indication for an EPS, ex-
cept for Brugada syndrome. In Brugada syndrome, EPS may be useful
in asymptomatic patients with spontaneous or drug-induced type 1
pattern, especially when there is a family history of sudden death.75–77
Implantable loop recorders
Implantable loop recorder to diagnose unexplained
syncope/atrial fibrillation with cryptogenic stroke
The implantable loop recorder (ILR) provides long-term continuous
monitoring and improves the diagnosis in patients with unexplained
syncope.81 In a meta-analysis of 49 studies that included 4381 partici-
pants, the diagnostic yield for the detection of arrhythmogenic syn-
cope was 26.5%.78 Moreover, the CRYSTAL-AF trial80 revealed that
the ILR can detect subclinical AF following cryptogenic stroke. Still,
any benefit of these findings needs to be confirmed in large random-
ized trials. Early use of the ILR has been advocated by the European
guidelines82 and in the American guidelines following inconclusive
non-invasive monitoring.83 The indications for ILR have been ex-
panded in the current guidelines (Table 2).
Implantable loop recorder to diagnose atrial and
ventricular arrhythmia events
While the ILR can be useful to detect atrial and ventricular arrhythmias,
a large cohort study indicated that most of the current use of ILRs is
primarily in patients with unexplained syncope (84%), followed by
palpitations (13%), and suspected AF (12%).79 Another smaller study
specifically studying the risk of SCD and arrhythmias in patients with
haemodialysis, found that 20% of these patients had SCD or bradyar-
rhythmia events necessitating pacemaker implantation, and 33% of
these patients had an arrhythmic endpoint. Interestingly, the median
time to event was 2.6 years, confirming the need for long-term moni-
toring. Surprisingly however, bradyarrhythmias were very commonly
diagnosed in this cohort suspected to be at high risk for ventricular
arrhythmias and sudden cardiac death.84 Further studies are needed to
establish the role of ILR in risk stratification.
Wearables/direct to consumer
.................................................................................................
Implantable cardiac devices Class References
An ILR is indicated in the evaluation
of patients with infrequent recur-
rent syncope of uncertain origin
especially when ambulatory moni-
toring is inconclusive.
78–80
An ILR is indicated in patients with
syncope and high-risk criteria in
whom a comprehensive evalua-
tion did not demonstrate a cause
of syncope or lead to a specific
treatment, and who do not have
conventional indications for pri-
mary prevention ICD or
pacemaker.
78–80
An ILR can be considered in patients
with palpitations, dizziness, pre-
syncope, frequent premature ven-
tricular complexes (PVCs)/non-
sustained VT, and in those with
suspected AF, and following AF
ablation.
78–80
................................................................................................
Table 2 High-risk and low-risk criteria for syncope at
initial evaluation (Adapted from 2018 ESC Guidelines
for the diagnosis and management of syncope82)
Syncopal events
Low-risk
Associated with prodrome typical or reflex syncope (e.g. light-
headedness, feeling of warmth, sweating, nausea, vomiting)
After sudden unexpected unpleasant sight, sound, smell, or paina
After prolonged standing or crowded, hot places
During a meal or postprandial
Triggered by cough, defaecation, or micturition
With head rotation or pressure on carotid sinus (e.g. tumour, shav-
ing, tight collars)
Standing from supine/sitting position
High-risk
Major
New onset of chest discomfort, breathlessness, abdominal pain,
or headache
Syncope during exertion or when supine
Sudden onset palpitation immediately followed by syncope
Presence of structural heart disease especially left ventricular
dysfunction and/or history of myocardial infarction
Minor (high-risk only if associated with structural heart disease or
abnormal ECG):
No warning symptoms or short (<10 s) prodrome
Family history of sudden cardiac death at young age
Syncope in the sitting position
aSudden loud sounds (as an alarm clock) may trigger VF in some long QT syn-
drome patients.
ECG, electrocardiogram; VF, ventricular fibrillation.
.................................................................................................
Wearables/direct to consumer Class References
Wearables may provide diagnostic
data that contribute to disease
detection and management when
integrated into the clinical con-
text and physician judgement.
85,86
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The direct to consumer or wearable technology market, comprised
of devices that monitor physiological parameters such as heart rate
and sleep pattern, is anticipated to grow to 929 million connected
devices by 2021.87 These devices encompass wristbands, glasses, in-
ear monitors, chest straps, and smart phone-enabled recording elec-
trode systems or electronic shirts, with varying capacity to monitor
heart rate, heart rhythm, blood pressure, physical activity, respiratory
rate, blood glucose, and sleep patterns.88–90 For heart rate monitor-
ing, most wearable devices use photoplethysmography (PPG) tech-
nology, meaning they are inherently less accurate than conventional
electrocardiography monitoring techniques. Accuracy of various
devices varies, with correlation to reference standard ECG monitor-
ing ranging from 0.76 to 0.99.91 Recent advances in wearable ECG ac-
quisition include use of direct electrode recording that represents a
regulatory approved medical device generating a lead I like rhythm
strip, blurring the lines between consumer and medical devices.92
A growing body of evidence suggests that these technologies can be
harnessed to facilitate arrhythmia detection in the appropriate context.
Although marketed as consumer devices, many wearable devices may
generate health data comparable to that of medical grade ECG moni-
tors, with several devices migrating to approved medical use.85
Despite this promise, there are clear concerns regarding accuracy, par-
ticularly false positives in asymptomatic patients where device-based
alerts can raise unwarranted concern and generate low yield screening
for disease, with associated costs. Wearable technologies represent an
important frontier in health evaluation, with the potential to provide
readily accessible health data for large segments of the population, in-
cluding those not captured by conventional monitoring techniques.
Though intended for personal use focused on health promotion and
physical activity, wearable technologies promise to invert the tradi-
tional paradigm of healthcare delivery, with data collection and health
queries often initiated by consumers and not providers. Providers may
see wearables as accessible risk stratification tools for detection of AF
in high-risk cohorts (such as high CHADS2-VASC2 score patients), and
patients may equally present for evaluation after device-based observa-
tions that call into question whether they are at risk. The confluence of
these factors is illustrated in the recently presented Apple Heart Study,
wherein 419 297 participants were recruited in only 8 months to par-
ticipate in an AF screening study that deployed a PPG-based algorithm
followed by a 7-day patch if AF was suspected.93 Using a complex
tachogram algorithm, 2126 individuals were sent irregular pulse notifi-
cations and prompted for a telemedicine visit and 7-day ECG patch.
The authors reported a PPV of 84% for each irregular pulse notifica-
tion, and 71% for each irregular tachogram. The burden of notifications
and the performance of the technology showed promise to inform AF
detection in the broader public. Similarly, the Huawei Heart Study eval-
uated 187 912 individuals that used smart devices to monitor their
pulse rhythm, with notification of suspected AF in 424 participants,
with a strong relationship between advancing age and detecting AF.
The predictive value of the algorithm in the 62% of notified participants
that pursued medical evaluation was promising (87%).94
Studies evaluating PPG-based wearables in conjunction with
machine-learning algorithms have shown promise in arrhythmia de-
tection, such as AF.86 Studies to date have not focused on ventricular
arrhythmia detection. Future wearables will benefit from improved
reliability and accuracy, collect additional health and fitness
parameters, support chronic disease management, and provide real-
time connectivity and feedback that may supplant conventional medi-
cal monitoring. Wearables have the potential to become truly disrup-
tive in our healthcare sector, with large segments of the population
accessing cardiac monitoring that the physician must interpret.
Currently, we have no data on how the information provided by
PPG-based wearables will affect management and outcomes of
patients, or how risk scores derived in other populations such as the
CHA2DS2VASc score apply in these previously undetected subjects.
Biomarkers, tissue, genetics
The use of biomarkers, tissue biopsy, and genetic assessment can be
used for risk assessment in patients suspected of specific arrhythmias
or syndromes. The utility of using these tools broadly spans deter-
mining arrhythmic risk, refining a clinical diagnosis and estimating
prognosis.
Biomarkers
Cardiac myocytes express and secrete natriuretic hormones that
have a central function on blood pressure regulation, blood volume,
and plasma sodium balance. Levels of B-type natriuretic peptide
(BNP) and its stable N-terminal peptide pro-BNP (NT-proBNP) are
increased in AF.101 AF burden has been shown to be associated with
increased NT-proBNP.102 In a large meta-analysis consortium, BNP
and C-reactive protein (CRP) associate with AF but only BNP was su-
perior to well-known clinical variables in AF risk prediction.103
Inflammatory processes and fibrosis are central to pathogenesis of
AF,106,109 and the inflammatory marker CRP is associated with longer
.................................................................................................
Biomarkers, tissue, genetics Class References
Genetic testing should be consid-
ered in several inherited arrhyth-
mic diseases associated with an
increased risk of ventricular ar-
rhythmia and SCD.
95–97
MRI with LGE to detect fibrosis and
scar may be useful in assessing the
risk of arrhythmic events in AF
patients and patients with
cardiomyopathies.
98–100
Plasma NT-proBNP may be useful in
differentiating patients with higher
vs. lower burden of AF.
101–105
Plasma CRP or other inflammatory
markers may be useful in risk as-
sessment, for identifying individu-
als with increased risk of future
AF and for identifying individuals
with high degree of atrial fibrosis.
106–108
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AF duration and atrial remodelling.110 CRP levels are elevated in
patients with permanent AF compared to persistent AF patients and
are predictive of recurrent AF after catheter ablation,111,112 indicating
that CRP levels can be used to identify AF subtypes and evaluate
prognosis. Higher levels of CRP correlated to an increased risk of de-
veloping AF in general and after acute myocardial infarction.107,113
Similarly, the plasma protein YKL-40 may have diagnostic and prog-
nostic use in AF patients108 because plasma serum chondrex (YKL-
40) is associated with atrial fibrosis severity in patients with lone
AF.114 Patients who experience recurrent AF following ablation have
significantly increased YKL-40 baseline levels, although plasma YKL-
40 is not an independent predictor of recurrent AF.108,115 Increasing
levels of YKL-40 have been shown to associate with a two-fold in-
creased risk of future AF.116 Other simple AF biomarkers include
body weight and blood pressure, which are also major intervention
targets.117–122
Tissue diagnostics
Tissue diagnostics can be beneficial to differentiate various infiltrative
myopathic processes that can contribute to the risk for arrhythmic
events. Fibrosis and scarring are well-recognized substrates for ar-
rhythmia both in atria and ventricles.109 Fibrosis may be assessed in
atria as well as in ventricular myocardium and its quantification can be
used in evaluating the risk of arrhythmia in AF and cardiomyopa-
thies.98,99 Specific patterns of scarring can assist in refinement of the
diagnosis for infiltrative myopathies, hypertrophic cardiomyopathy,
sarcoidosis, ACM, and amyloidosis. The development and validation
of advanced imaging techniques including bio-metabolic imaging (sar-
coid), and contrast enhanced cardiac MRI (amyloid) have largely
replaced the need for invasive diagnostics.
Genetics
The majority of clinically applicable genetic testing is intended to be
driven by phenotype and the pre-test probability of specific diagnosis
determines the utility of genetic investigation.95 Due to incomplete
penetrance of genetic arrhythmia syndromes, harbouring a genetic
variant with known pathogenicity is almost never solely enough to
meet diagnostic criteria for a particular syndrome.123
For LQTS, part of the diagnostic framework (along with the
ECG biomarker of QT prolongation) can include a positive genetic
test.123 Moreover, understanding the genetic diagnosis is impor-
tant for treatment and prognostication. For example, patients with
Jervell and Lange-Nielsen and Timothy Syndrome patients (LQT8)
have more malignant clinical courses,124,125 and for LQT1 the ar-
rhythmic risk depends partly on which region of the channel the
mutation affects.126 In catecholaminergic polymorphic ventricular
tachyarrhythmia (CPVT),127 genetic testing of suspected individu-
als has a moderately high yield.95 Identification of an at risk first-de-
gree relative of a CPVT affected individual is essential due to the
high penetrance but more so the lethality of this syndrome.123,128
Similar to LQT1, CPVT due to RYR2 mutations may have some de-
gree of risk depending on where in the ryanodine receptor the mu-
tation falls.129 Brugada syndrome can be particularly difficult to
clinically diagnose and the utility of genetic testing for improving di-
agnosis is poor. For patients who are clinically diagnosed with
Brugada Syndrome the yield of genetic testing is 30%,130 the
majority of whom harbour SCN5a mutations, a gene associated
with a plethora of arrhythmia syndromes.131,132 Genetic testing
can be useful for family members of an appropriately genotype
identified proband but is not recommended in the absence of a di-
agnostic ECG.95 Using genetics as part of diagnostic criteria for
arrhythmogenic cardiomyopathies will be discussed later in the
document. Lastly, genetics in AF is a developing area, but certain
primary electrical sudden death syndromes have increased AF as-
sociation as discussed in Patients with inherited rhythm disease
(long QT syndrome/short QT syndrome/catecholaminergic poly-
morphic ventricular tachyarrhythmia/Brugada syndrome) section.
For families with a substantial number of AF cases or in early onset
AF, genetic testing can be considered but the yield is low.133–136
Artificial intelligence
Machine learning is a broad term of artificial intelligence derived from
the extraction of patterns from large data sets. The marriage with
healthcare analytics and decision processes has been rapidly for-
warded with computerized medical records and the creation of large
data warehouses.
A deep neural network was created to analyse raw ECG data from
an ambulatory heart monitor and classify it into 12 categories based
upon the presence of arrhythmia. Machine learning performed very
well with an average under the reviewer operating characteristic
curve (ROC) of 0.97 and an average F1 score (mean of the PPV and
sensitivity) of 0.837; a score better than an average cardiologist
(0.780).137
Machine learning has been applied to standard ECG characteristics
in sinus rhythm to predict incident AF using the eight independent
ECG leads (leads I, II, V1–6) through a convolutional neural net-
work.138 The ROC area under the curve for the detection of AF was
0.87 (0.86–0.88) using the internal validation dataset and 0.87 (0.86–
0.88) using the testing dataset.
In an analysis of the Atrial Fibrillation Prediction Database, a ma-
chine learning approach based upon heart rate variability predicted
onset of AF with sensitivity of 100%, specificity of 95.6%, and accuracy
of 96.2%.139 Machine learning based upon ECG characteristics identi-
fied left ventricular dysfunction with an area under the curve of 0.93,
sensitivity of 86.3%, and specificity of 85.7% including risk of left ven-
tricular dysfunction in those without.140
Machine learning has shown accuracy in predicting mortality and
risk stratification of patients with CAD.141 Machine learning has also
been shown to accurately discriminate between athletic hearts com-
pared to hypertrophic cardiomyopathy hearts.142 Machine learning
has great potential in this area of risk assessment because of the large
amount of data contained in the large ECG and clinical datasets avail-
able to determine rules.
How to assess risk for atrial
fibrillation in specific populations
Patients of advanced age
There is agreement that the prevalence of AF in the general
population in the Western world is in the order of 1–2%.143–145
It is estimated that in 2010 there were 33.5 million people in
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the world with AF of which 20.9 million were men and 12.6 million
were women.146 During the past 20 years, the age-adjusted preva-
lence rates of AF increased for both men and women and similarly
the corresponding incidence rates have increased.146–150 Age is a
major risk factor for the development of AF and in persons youn-
ger than 55 years a prevalence of AF around 0.5% is seen whereas
in persons older than 85 years AF prevalence is around 15%
(Figure 1).144 A stepwise increase in AF prevalence with increasing
age has been found in several studies.152,153 Studies in a multi-
ethnic cohort from the United States has shown large variation in
AF prevalence among various race-ethnicity groups in which AF
associated hospitalizations were lower in Hispanics, Chinese, and
Black Americans compared to White Americans.153 The predomi-
nant contributor to the increasing AF prevalence is our aging pop-
ulations, more widespread use and availability of screening tools,
and improved treatment for various heart diseases that enhance
longevity.
Among AF patients, those aged younger than 65 years are in gen-
eral healthier than those older than 65 years.154 Life time risks of AF
in 55-year-old subjects without a history of AF have been found to be
20–24% in the Rotterdam study155 but considerably higher at 37% in
the Framingham study.134 The lifetime risk of AF in Asians older than
20 years (1 in 6 for men and 1 in 7 for women; i.e. 14–17%) was lower
than the risk reported from Western countries.156
The incidence rates, prevalence, and lifetime risk of AF are higher
for men than women. Despite this, the absolute number of women
with AF exceeds the total number of men with AF because women
live longer than men.144 Women have their first episode of AF about
5 years later than men and less commonly have lone AF.144 In general,
women with AF are more likely to have hypertension or valvular
heart disease compared to men.144 Women often present with atypi-
cal symptoms related to AF (Figure 2). On the other hand, compared
to men, women are less likely to have asymptomatic AF, they have a
higher symptom burden, they have higher average heart rate during
AF and more often longer lasting episodes of AF.144 These factors
contribute to the observation that women are more likely to contact
their physician due to AF-related symptoms compared to men.
Conflicting results exist with respect to risk of stroke secondary to
AF and its prognosis in women compared to men.157–159 There does
not seem to be a gender difference with respect to development of
dementia secondary to AF, although women have higher rates of de-
mentia than men in general.145,157
Since both AF and stroke are highly associated with age and stroke
may occur as a complication of AF it seems reasonable to consider
screening for this arrhythmia in elderly populations. Several studies
are ongoing and expected to be finalized within the next couple of
years. These studies are expected to guide us with respect to cost-
effectiveness of these screening strategies.
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Figure 1 A depiction of the atrial fibrillation prevalence distribution found by each study published to date.151 This depiction uses the sex-specific
average rates of AF prevalence, grouped by age. The thick line represents average AF prevalence rates by age group, as derived from a pooled analysis
of the individual studies weighted by sample size. (Adapted from Andrade et al. Circ Res 2014.) AF, atrial fibrillation.
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Patients with heart failure
Due to common risk factors like age, hypertension, diabetes, obesity,
and sleep apnoea, AF and HF are intricately linked and share common
pathophysiologic mechanisms. Atrial fibrillation occurs in more than
half of individuals with HF and presence of both carries greater mor-
tality risk compared with those without either condition.167
In the particular case of cancer treatment, HF is also a common
consequence of cardiotoxicity associated with some chemothera-
peutic agents, including anthracyclines, human epidermal growth fac-
tor receptor 2 (HER2), and proteasome inhibitors. In this setting,
isolated cases of AF have been reported. Even if the exact mechanism
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Investigations needed to assess risk for AF in patients with heart failure Class References
A careful evaluation of clinical characteristics known to be associated with increased risk for
AF should be performed.
160
Frequent interrogation or remote monitoring of stored arrhythmia episodes in device
implanted HF patients should be performed in order to diagnose AF and allow its early
management.
161
Echocardiography is useful in identifying cardiac characteristics associated with a higher risk
for AF.
162
Cardiac MRI may be considered in identifying degree of atrial fibrosis and scar. 163
Use of biomarkers may be considered for identifying individuals with increased risk of future
AF and for identifying individuals with high degree of atrial fibrosis.
107,164,165
Searching for common genetic variants associated with AF risk by genetic molecular analysis
has not been found to be useful in a routine clinical setting.
166
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of these arrhythmias induced by such drugs remains largely unknown,
it seems plausible that the negative effect on the cardiac systolic func-
tion also plays a central role.168
Given the deleterious effects of AF in HF patients, significant inter-
est has been directed to risk factors predicting the development and
progression of this arrhythmia (Figure 3).
Clinical risk factors
Older age and male gender are associated with a higher risk of devel-
oping AF.160 Diabetes confers a 1.4- to 1.6-fold higher risk for AF.160
Because of its high prevalence in the general population, hyperten-
sion is responsible for more AF in the population (14%) than any
other risk factor.160 Obesity and sleep apnoea are independent risk
factors for AF.169 AF incidence also increases in case of renal or thy-
roid dysfunction.170,171
With regard to HF and the type of underlying heart disease, preva-
lence of AF increases significantly with the severity of HF symptom-
atology. Among the valvular diseases, the left-sided valve stenoses
have the highest prevalence rates of AF. In addition, the presence of
CAD or hypertrophic cardiomyopathy is a significant risk factor for
incidence and progression of AF.172 Finally, in congenital heart disease
patients, substantial AF rates appear decades before their onset in
the general population.173
Electrocardiography
Electrocardiogram-derived variables, such as the PR interval, ECG-
based left ventricular hypertrophy (LVH), P wave indices like P wave
duration, area, and terminal force have been used in various AF pre-
diction models but their additive value over other clinical risk factors
is minimal.174 Short duration Holter monitoring is not useful for AF
detection in asymptomatic patients. Longer duration monitoring with
external or implantable loop recorders may help when paroxysmal
AF is suspected. In addition, frequent interrogation or remote moni-
toring of Holter memories in device implanted HF patients is manda-
tory in order to diagnose AF and allow its early management.161
Biomarkers
Markers of inflammation (high-sensitivity CRP, fibrinogen), atrial
overload (atrial and B-type natriuretic peptides), myocardial ischae-
mia (high-sensitivity troponin T and I), cardiac fibrosis (galectin-3),
and others (soluble ST2, growth differentiation factor-15), have been
studied to predict AF incidence.165 Of these, only natriuretic peptides
have consistently demonstrated added predictive value beyond infor-
mation on clinical variables.164,165
Imaging
Many echocardiographic variables have been associated with a signifi-
cantly higher AF recurrence rate. Possibly, left atrial volume is supe-
rior to left atrial diameter in predicting progression to persistent AF.
Speckle left atrial strain and stiffness index can also predict the main-
tenance of sinus rhythm after cardioversion for AF.162
Concerning MRI, the amount of left atrial enhancement quantified
on MRI with LGE may be helpful to predict progression of AF,163 but
the reproducibility of such findings remains controversial.
Genetics
A family history of AF in a first-degree relative independently
increases AF risk two-fold.175 Recent research has identified several
common genetic variants associated with the risk of AF.136 Further
studies are required to evaluate whether genetic information
improves our ability to predict AF on top of clinical variables.
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Risk assessment of AF in patients with HF can be carried out at first
by considering the clinical features, comorbidities, and underlying aeti-
ologies. It can be further refined by more sophisticated investigations.
Patients with obesity, hypertension,
diabetes, sleep apnoea, or structural
heart disease
The assessment of underlying AF in people at higher risk for AF can
be considered from opportunistic perspective, or the consideration
of clinical risk prediction tools.180 Many patients with common condi-
tions that may predispose to AF, such as obesity, sleep apnoea, hy-
pertension, or SHD should or would be attending specialist clinics for
their assessment and/or follow-up. Hence, an opportunistic strategy
of pulse palpation and clinical assessment (e.g. symptoms) followed
by appropriate ECG monitoring to confirm AF would be an appropri-
ate and cost effective method for screening.181 In general, clinical
scores have been less useful as most only have modest predictive
value for identifying the population at risk; ultimately, these patients
would also require their AF documented. A strategy of using risk
scores to target high-risk patients for more intense screening efforts
merits consideration.
The systematic review by Allan et al.176 found that in relation to
the relative risk of incident AF:
• For every 1–10 kg/m2 increase in body mass index (BMI), or BMI
>_25–30 kg/m2, all 19 reports showed significant direct associations
(from 1.04 [1.02–1.05] to 2.24 [1.41–3.58]).
• For every 10–22 mmHg increase in systolic blood pressure, or
systolic blood pressure >_160 mmHg, most reports showed signifi-
cant direct associations (from 1.14 [1.05–1.25] to 2.63 [1.83–
3.78]).
• For diabetes mellitus (type unspecified), eight reports showed a di-
rect but non-significant (from 1.02 to 1.49) and six reports
showed significant direct associations (from 1.17 [1.16–1.19] to
1.80 [1.30–2.60]).
Many of these conditions are present concomitantly. Also, obesity
and hypertension are commonly associated with sleep apnoea, which
is another risk for incident AF.
Obesity has been associated with incident AF,182 but clinical trial
data have a suggestion of an ‘obesity paradox’ whereby overweight
AF patients tended to have improved outcomes; however, the rela-
tionship between obesity and outcomes from real-world observa-
tional cohorts are less clear.183–185 In a systematic review of trial and
real-world evidence, there was suggestion of an obesity paradox in
AF patients, particularly for all-cause and cardiovascular death out-
comes.184 An obesity paradox was also evident for stroke/systemic
embolic event outcomes in the non-vitamin K antagonist oral antico-
agulant (NOAC) trials, with a treatment effect favouring NOACs
over warfarin for both efficacy and safety that was significant only for
normal weight patients. Nonetheless, proactive management of obe-
sity is part of the lifestyle advice for patients with AF.
On a population basis, hypertension is the most common aetiolog-
ical factor for AF, and contributes to its complications. Indeed, AF
can be regarded as a manifestation of hypertension target organ dam-
age. The optimal blood pressure targets in AF patients have been de-
scribed, being 120–129/<80 mmHg.186 Also, longer hypertension
duration is associated with the increased risk of ischaemic stroke;
however, this long-term effect of hypertension duration can be atten-
uated by long-term strict SBP control throughout the entire duration
of hypertension.187
Poor diabetes control is associated with incident AF. In the dia-
betic AF patient, longer disease duration is related to a higher risk
of stroke/thromboembolism in AF, but not with a higher risk of
anticoagulant-related bleeding.188 These risks were similar for
Type 1 and Type 2 diabetes.189 Evidence of other target organ
damage such as diabetic retinopathy increased risk, although it did
not add to the predictive value of risk assessment using the
CHA2DS2-VASc score.
190 Indeed, the ATRIA study also con-
firmed that duration of diabetes is a more important predictor of
ischaemic stroke than glycaemic control in patients who have dia-
betes and AF.191
Unsurprisingly SHD is a potent risk factor for incident AF, as
well as its complications, such as stroke and HF.177,192 Systolic HF
is one of the components of the simple C2HEST score [Chronic
obstructive pulmonary disease and CAD [1 point each]; hyperten-
sion [1 point]; elderly [age >_75 years, 2 points]; systolic HF [2
points]; thyroid disease [hyperthyroidism, 1 point])] which has
been derived and validated in a large cohort of AF patients.177
This score could potentially be considered to target the high-risk
patients that may be suited for more intense screening for inci-
dent AF, e.g. post-stroke where the C2HEST score was superior
to the other scores such as the Framingham score.178 The risks of
AF with associated valvular heart disease are well recognized, as
recently discussed in an EHRA position document.193 In terms of
HF, there is a link between AF complications and HF, whether HF
with a reduced EF (HFrEF) or HF with a preserved EF (HFpEF).194
In the CHA2DS2-VASc score, the ‘C’ component refers to recent
decompensated HF, irrespective of the EF, or the presence of
moderate-severe systolic dysfunction whether asymptomatic or
not.7 Of note, the CHA2DS2-VASc score is predictive of stroke in
HF, whether or not AF is present.195
.................................................................................................
Patients with obesity, hyper-
tension, diabetes, sleep ap-
noea, or structural heart
disease
Class References
Clinical risk factors should be
assessed to help identify incident
AF and its complications.
176
Clinical risk scores may be useful to
identify risk for incident AF.
177–179
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Patients who have undergone cardiac
surgery
Post-operative AF remains the most common complication following
cardiac surgery and its incidence ranges between 20–50% across nu-
merous studies.196 This risk increases from isolated CABG surgery,
to valvular surgery, and in turn to concomitant CABG/valvular
surgery.
Risk factors for developing AF may be divided into procedural- and
patient-related factors. Procedural-related risk factors include type of
surgery, mitral valve surgery, use of intra-aortic balloon pump, longer
cardiopulmonary bypass and aortic clamp times, and perioperative
issues such as inflammation, infection, fluid overload, inotropic use,
atrial ischaemia, hypokalaemia, and hypomagnesaemia. Patient-
related risk factors include advanced age, history of AF, history of HF,
renal failure, hypertension, chronic obstructive pulmonary disease,
post-operative withdrawal or absence of beta-blocker, or angioten-
sin-converting enzyme inhibitor (ACE inhibitor) therapy.197,200 Left
atrial remodelling predisposes to post-cardiac surgery AF, with risk
factors such as enlarged left atrial size, diastolic dysfunction, LVH,
obesity, obstructive sleep apnoea, and the CHADS2 and CHA2DS2-
VASc score further predisposing to post-operative AF.197,201,202
The majority of post-cardiac surgical AF occurs within the first 4
post-operative days, and is most common on the 2nd post-operative
day, while recurrences are most common on the 3rd post-operative
day.197,203 In another study of CABG patients, 94% of post-operative
AF occurred by the 7th post-operative day.198 Hence rhythm moni-
toring such as inpatient telemetry or ECG for post-operative AF
should focus on this time frame.
While post-cardiac surgical AF likely occurs as a result of the inter-
action between acute perioperative triggers and the underlying atrial
and cardiac substrate, its occurrence identifies a subset of patients as-
sociated with long-term morbidity and mortality. In a study of
patients who underwent CABG, post-operative AF conferred an
eight-fold increased risk of future AF and doubled cardiovascular
mortality on long-term follow-up.199 Follow-up rhythm monitoring,
for example with ECG or Holter monitoring is advisable in this subset
of patients particularly in the setting of symptom development. There
is emerging data on the use of implantable cardiac monitors for long-
term monitoring of this subset of patients. While implantable cardiac
monitors allow continuous long-term monitoring for arrhythmias
and asymptomatic arrhythmias, the risk–benefit ratio is balanced by
the arrhythmia detection rate beyond the immediate post-operative
period and level of invasiveness of the monitoring device. Its routine
use will depend on further results from prospective medium to long-
term studies.
Patients with cryptogenic stroke
Cryptogenic stroke is defined as ischaemic stroke of undetermined
aetiology.208 The diagnosis of cryptogenic stroke is generally made by
exclusion. Although cryptogenic stroke includes few potential causes,
such as paradoxical embolism through a patent foramen ovale, atrial
septal aneurysm, and aortic arch atheroma, the majority of cases are
thought to be caused by cardio-embolism due to undetected parox-
ysmal AF.205 For the diagnosis of cryptogenic stroke or a suspected
transient ischaemic attack (TIA), patients should initially undergo
brain imaging. Diffusion-weighted MRI is more recommended than
any other MRI sequence or CT as brain imaging, except when contra-
indicated.204,205 Advances in cardiac imaging techniques such as trans-
oesophageal echocardiography (TOE) have prompted the
reassessment of cryptogenic stroke because most cases are
thought to be embolic due to a cardiogenic source, mainly AF.
.................................................................................................
Patients who have undergone
cardiac surgery
Class References
Heart rhythm monitoring for 4–7
days is recommended for detec-
tion of post-operative AF.
196–198
Patients with post-operative AF may
undergo follow-up rhythm moni-
toring to assess for the presence
of symptomatic and asymptomatic
arrhythmias.
196–199
.................................................................................................
Patients with cryptogenic
stroke
Class References
Patients should initially undergo
brain diffusion-weighted MRI im-
aging for the diagnosis of crypto-
genic stroke.
204,205
AF is more likely to be detected af-
ter cryptogenic stroke with more
intense investigation with longer
and more sophisticated
monitoring.
205–207
Long-term ECG monitoring techni-
ques, such as trans-telephonic
ECG monitoring or cardiac event
recorders or ILR can increase
yield of AF diagnosis after crypto-
genic stroke in selected patients.
205,206
The use of an ILR should be consid-
ered for detecting AF in selected
patients who are at higher risk of
AF development, including the el-
derly, patients with cardiovascular
risk factors or comorbidities.
80,207
TOE may lead to the reclassification
of cryptogenic stroke because
many cases are embolic and due
to a cardiogenic source, mainly
AF.
205,206
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Transoesophageal echocardiography can easily detect a thrombus of
the left atrial appendage, particularly with contrast enhancement,
which cannot be detected using conventional transthoracic echocar-
diography. Transthoracic echocardiography with contrast could be
useful to detect a left ventricular thrombus (Figure 4).
The detection of permanent or persistent AF is relatively easy,
whereas that of paroxysmal AF is more difficult. Current guidelines
recommend the use of ECG monitoring among patients with ischae-
mic stroke including cryptogenic stroke and TIA for whom transient
(paroxysmal) AF is suspected and no other causes of stroke are iden-
tified.205,206 First, 24-h Holter ECG is performed to detect the AF
burden. If undetected, other long-term ECG monitoring techniques
such as trans-telephonic ECG monitoring or cardiac event recorders
(a symptom event monitor or a ILR) may be attempted as alternative
methods. A meta-analysis indicated that a longer duration of ECG
monitoring is associated with an increased detection of new AF when
examining monitoring time as a continuous variable. Studies with
monitoring lasting <_72 h detected new AF in 5.1% of cases, whereas
monitoring lasting >_7 days detected AF in 15% of cases.209 The pro-
portion of new diagnosis of AF was increased to 29.1% with
3-months extended monitoring. Recently, smartphone-based ECG
recording systems have been developed and conferred acceptable
sensitivity and specificity of detecting AF191 (see Wearables/direct to
consumer section).
The use of an ILR is indicated for detecting the presence of AF or
arrhythmia burden that might cause ischaemic stroke in selected
patients, for example those who are at higher risk of AF development
including elderly, patients with cardiovascular risk factors or comor-
bidities. An ILR is a useful tool for detecting arrhythmias. In the
CRYSTAL AF study, AF was newly detected in 8.9% of patients with
an ILR by the 6th month compared with 1.4% among those receiving
conventional ambulatory ECG monitoring, increasing further to
12.4% by 12 months compared with 2.0% in conventional monitor-
ing.80 A similar outcome was observed in the EMBRACE trial, in
which AF was newly detected in 16.1% of patients who received 30-
day ILR compared with 3.2% who received ambulatory 24-h moni-
toring.210 A systematic review indicated that AF was newly detected
in nearly one-quarter of patients with stroke or TIA by sequentially
combining cardiac monitoring methods: 7.7% in phase 1 (emergency
room), 5.1% in phase 2 (in-hospital), 10.7% in phase 3 (first ambula-
tory period), and 16.9% in phase 4 (second ambulatory period con-
sisting of trans-telephonic ECG monitoring, cardiac event recorders,
and ILR), and 23.7% in the overall detection after all phases of se-
quential ECG monitoring.207 Thus, if we ‘look harder, look longer
and look in more sophisticated ways’ we are more likely to detect
AF. It is possible that if we use clinical risk stratification (e.g. the
C2HEST score) to identify patients post-stroke at high risk of inci-
dent AF, targeted intensive monitoring can be applied.211
How to assess high risk of atrial
fibrillation in professional athletes
Atrial fibrillation risk in athletes—general
Paroxysmal or persistent AF is common in athletes and may be auto-
nomically mediated or triggered by other supraventricular tachycar-
dias.215 AF is the primary arrhythmia observed in middle-aged
athletes.216 AF in athletes tends to be paroxysmal, vagally mediated,
and highly symptomatic.213 The mechanism of increased AF risk at ei-
ther end of the physical activity spectrum likely includes autonomic,
structural, inflammatory, and fibrotic changes to the heart. For exam-
ple, increased vagal tone, which is often observed in the endurance
athlete, has been shown to result in a short atrial refractory period,
and thus initiates AF.217
Atrial fibrillation risk in athletes—exercise paradox
Recent studies have observed a U-shaped risk relationship of physical
activity to AF. At one end of the spectrum, a large observational
study218,219 of people showed that those at the lowest levels of physi-
cal fitness had a 5-fold increased risk of AF.220 Increasing the physical
activity of sedentary patients could help reduce the risk or burden of
AF. Long-term endurance training, as well as a sedentary lifestyle,221
increase chronic systemic inflammation, which in turn could also facil-
itate AF.106 For example, one randomized study demonstrated that
just 12 weeks of moderate-intensity physical activity decreased the
AF burden by 41%.222 Of the physically inactive with AF, the obese
When ischemic stroke is suspected
If cerebral embolism is suspected
If AF or intra-atrial thrombus is not detected
If any abnormality is not detected
If any abnormality is not detected
Medical interview and physical examination
Brain imaging
(Brain diffusion-weighted MRI scan or alternatively CT scan)
Assessment of cardiogenic source
24-h Holter ECG, long-term ECG monitoring, and echocardiography
Carotid artery imaging
(Doppler of Carotids, MR/CT angiography, or catheter angiography)
TEE, deep venous ultrasonography, aortic CT, specific blood test, and so 
on
Indication of ILR
Figure 4 Proceeding of evaluation for cryptogenic stroke. AF,
atrial fibrillation; CT, computed tomography; ECG, electrocardio-
gram; ILR, implantable loop recorder; MRI, magnetic resonance im-
aging; TOE, transoesophageal echocardiography.
.................................................................................................
Atrial fibrillation in athletes Class References
In athletes who participate long
term in endurance exercises with
symptoms of arrhythmia screen-
ing for AF is recommended.
212
Risk assessment for AF risk in ath-
letes may include the duration
and intensity of exercise as a po-
tential modifiable risk factor.
213,214
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might benefit the most from moderate levels of physical activity.220 In
contrast, a meta-analysis of 655 endurance athletes also demon-
strated a five-fold increased risk of AF.212 Of these studies, increased
AF risk was generally only observed with the highest levels of physical
activity that was maintained over a prolonged period of time.213,214
One uniform explanation for the exercise paradox is that both long-
term endurance training and a sedentary lifestyle increase chronic
systemic inflammation.
Atrial fibrillation risk in athletes—structural cardiac
changes
Most studies have shown structural changes in endurance athletes,
which have resulted in the term athlete’s heart. These changes in-
clude dilatation of all four heart chambers, increase in left ventricular
mass, and mild right ventricular hypertrophy.223 Studies show
that moderate physical activity might reduce inflammatory
markers.224–226 Extreme levels of exercise are a known cause of car-
diac fibrosis, particularly in hinge point locations of the heart, such as
the right ventricle; however, the significance of MRI-detected fibrosis
remains controversial.227 Athletes who experience higher levels of fi-
brosis also have higher levels of coronary calcium.228 In turn, fibrosis
is a well-established risk factor of AF.163 In one study, the fibrotic
changes caused by vigorous exercise were reversed after an 8-week
period of physical activity cessation.229 Among young elite athletes,
age, years of competition, and echocardiographically measured
parameters, including left atrial anterior–posterior diameter and atrial
strain, were associated with higher AF risk.230,231 Although increasing
physical activity might reduce AF in sedentary patients, decreasing
physical activity levels in elite endurance athletes may also reduce
AF.215 Currently, the role of deconditioning to lower AF risk in elite
athletes for primary or secondary prevention of arrhythmia requires
prospective evaluation.
Patients with inherited rhythm disease
(long QT syndrome/short QT syndrome/
catecholaminergic polymorphic
ventricular tachyarrhythmia/Brugada
syndrome)
Some patients with primary electrical sudden death syndromes have
an increased AF association, including Brugada Syndrome, LQTS,
SQT, and catecholaminergic polymorphic ventricular tachycardia
(CPVT). These patients are at risk for arrhythmia symptoms from AF
and are vulnerable to AF consequences such as pro-arrhythmia and
inappropriate ICD shocks.
Brugada Syndrome is characterized by ST-segment elevation in the
precordial ECG leads and increased risk of SCD due to VF.235
Brugada Syndrome is associated with a higher incidence of SVTs, and
AF is the most common SVT in these patients.236,237 AF susceptibility
has been described with patients harbouring mutations in SCN5A,
CACNA1C and patients without an identified genotype,234,238 sug-
gesting a lack of genetic AF specific risk but AF may be more preva-
lent with more advanced disease.239,240 Importantly, AF events can
be pro-arrhythmic for Brugada Syndrome patients123,241 and contrib-
ute to the high inappropriate ICD shock rates for Brugada Syndrome
patients.241
Long QT syndrome is a genetically heterogeneous syndrome asso-
ciated with mutations in 17 different genes with some unique pheno-
typic characteristics based on genotype and electrically results in
prolonged repolarization and risk for fatal ventricular arrhythmia tor-
sade de pointes. While generally, prolonged repolarization inhibits
AF initiation and this is the mechanism for Vaughn–Williams Class III
anti-arrhythmic drugs, rare patients with LQTS have also been noted
to have AF.242,243 This has been limited to single case reports and
unverified, 1.7% of patients in a LQTS cohort, which is a higher preva-
lence than the general population.133,244 Not surprisingly, some genes
associated with AF in LQTS have overlap with familial AF: LQT1
(KCNQ1), LQT2 (KCNH2), LQT3 (SCN5a), and LQT7 (KCNJ2).
However, for potassium channels, in LQTS the genetic defect results
in ‘loss of function’ in contrast to a ‘gain of function’ in familial
AF.245,246 It is less clear how prolonged repolarization results in AF
susceptibility but it may involve similar mechanisms to torsade de
pointes247 or perhaps dispersion of repolarization and induction of
early afterdepolarizations.248,249
From an electrical substrate standpoint, it is easier to understand
why SQTS and CPVT are associated with AF. Short QT syndrome is
a rare disorder caused by a gain of function of potassium channels
encoded by KCNQ1, KCNH2, and KCNJ2, causing a shortening of
the action potential and manifests in the atrium by a decreased atrial
refractory period and electrical substrate for AF.250–252 CPVT is an
autosomal dominant disorder associated with polymorphic VT and
bidirectional VT due to cellular calcium overload caused by muta-
tions in calcium handling genes.253–255 A reciprocal condition can ex-
ist in the atria of patients with CPVT with AF susceptibility and has
been shown to be more prevalent in patients with more dysfunc-
tional ryanodine receptor2 channels.256 It is also unclear how clini-
cally significant AF is for CPVT patients. However, the failure to
recognize and treat AF can result in inappropriate shocks, pro-ar-
rhythmia, and death.232,233
These issues highlight the need for AF recognition, ICD program-
ming to reduce the risk of inappropriate shocks, and preventative
treatment. Because of the small cohort sizes and lack of systematic
studies, it is difficult to prospectively estimate AF risk. Invasive EP
studies evaluating atrial refractory periods, conduction time, and AF
inducibility have been inconclusive236,237 and either not systematically
.................................................................................................
Patients with inherited rhythm
disease
Class References
Patients with certain inherited arrhyth-
mia syndromes are at higher risk for
AF and benefit from symptom-driven
and periodic surveillance.
123
Evaluation should include non-invasive
symptom-driven surveillance for
patients at risk for AF and periodic
non-invasive surveillance for asymp-
tomatic patients.
232–234
EPS to determine atrial AF substrate or
susceptibility is not useful.
123
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evaluated in large populations or are contraindicated (LQTS and
CPVT).123 We support vigilant non-invasive surveillance in these con-
ditions. For patients with ICD, close follow-up is needed to decipher
and to adjudicate if atrial arrhythmias are present and proactively in-
crease the rate cut-off for VF detection and turn SVT discriminators
on, if available. Patients without ICD, but suggestive symptoms,
should undergo ambulatory monitoring and asymptomatic patients
should have surveillance monitoring done every 1–2 years.
Treatment is not the focus of this article, but it should be recognized
that many AADs can worsen the electrical substrate for inherited ar-
rhythmia patients (i.e. LQTS, Brugada Syndrome) and care should be
taken when choosing antiarrhythmic drugs.
How to assess risk for adverse
outcomes in patients with atrial
fibrillation
Risk assessment for stroke/transient
ischaemic attack/cognitive decline
Patients with AF have increased mortality and morbidity compared
with non-AF patients and may experience significant adverse events.
Stroke and thrombo-embolic events are well known complications
that can be avoided by oral anticoagulation. Since the risk of individual
patient differs significantly, an individual risk assessment is necessary.
Several stroke risk scores, including ABC-stroke (age, biomarker,
clinical history), ATRIA (Anticoagulation and Risk Factors in Atrial
Fibrillation), GARFIELD (Global Anticoagulant Registry in the FIELD),
and Qstroke have been proposed as support tools for the decision
on oral anticoagulation.261–264 However, the one currently most
widely applied and recommended by international guidelines is the
CHA2DS2-VASc risk scheme. According to CHA2DS2-VASc, patients
with score of >_1 in a male or >_2 in a female should be considered for
stroke prevention strategies.265–268 Nevertheless, it has to be kept in
mind that no stroke risk scheme has perfect predictive accuracy.
Another major adverse effect of AF is impairment of cognitive func-
tion.258,259 Multiple risk factors for dementia have been identified in the
general population, including modifiable and non-modifiable ones.269
Apart from these AF-non-specific risk factors, AF may lead to cognitive
impairment by multiple mechanisms. These include apparent stroke, si-
lent stroke but also other mechanisms that are independent of throm-
boembolism.270 A detailed description of the association between AF
and cognitive impairment and possible preventive mechanisms has
been provided recently in an expert consensus document.258 In terms
of prevention of cognitive impairment in AF patients, there is evidence
that early and effective use of oral anticoagulation in patients with
stroke risk factors reduces the rate of cognitive decline and currently,
this represents the most important preventive strategy. Consequently,
the main risk assessment for cognitive impairment in AF patients is the
assessment of stroke risk factors, preferably by use of the CHA2DS2-
VASc risk scheme that can guide the decision on oral anticoagulation.
When cognitive impairment is suspected, brief screening tools such as
General Practitioner Assessment of Cognition (GPCOG), Mini Mental
State Examination (MMSE) and Montreal Cognitive Assessment
(MOCA), and Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) may be applicable.258 In addition, more comprehen-
sive assessments may be done after appropriate referral to a psychia-
trist, geriatrician, or neurologist.258
Risk assessment for stroke/transient
ischaemic attack status post-left atrial
appendage occlusion/ligation
.................................................................................................
Risk assessment for stroke/
TIA/Cognitive decline
Class References
A risk factor-based approach is rec-
ommended for stroke risk assess-
ment in patients with AF.
8,257
Cognitive assessment should be per-
formed in AF patients where
there is suspicion of cognitive
impairment.
258,259
Assessment of cognitive function
may be multifaceted, and cogni-
tive impairment screening by
available tools is just one
component.
258
Risk reduction of cognitive dysfunc-
tion and its comorbidities in AF
may include risk assessment for
vascular disease and/or
Alzheimer’s disease.
258,260
General health measures may re-
duce the concomitant risks of AF
and stroke, with a putative benefit
on cognitive function.
1,2
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Risk assessment for stroke/
TIA after LAA occlusion/
ligation
Class References
TOE after 6 weeks and if necessary
after 1 year is useful for detecting
peri-device residual flow, incom-
plete appendage ligation, or de-
vice-related thrombus to identify
patients at higher risk of stroke.
271,272
Clinical features such as previous
TIA/stroke, persistent AF, low
LVEF, vascular disease, and early
273,274
Continued
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Left atrial appendage (LAA) occlusion/ligation using one of several
devices or surgical techniques has been developed as an alternative
to anticoagulation in high-risk patients with non-valvular AF.279–281
The maximum experience has been with the Watchman device
(Boston Scientific), which has been found to be non-inferior to warfa-
rin in patients who are still candidates for short-term warfarin treat-
ment.282–284 Results of comparison between LAA occlusion/ligation
and NOACs are awaited. Current guidelines recommend use of LAA
occlusion as a possible strategy in patients having contraindications to
long-term anticoagulation.261
The residual risk of stroke/TIA following LAA occlusion/ligation
can be related to procedural or patient related risk factors. Among
the procedure related factors, peri-device leak, and device-related
thrombus are important factors for thrombo-embolic events in short
and medium term after the procedure. Stroke risk is significantly ele-
vated in patients in whom LAA ligation fails after surgical285 or percu-
taneous approaches.286
Post-procedure surveillance is therefore important to assess long-
term risk of stroke and need for continued anticoagulation. These
may be detected on TOE immediately or after few weeks/
months.271,272 Multidetector CT and cardiac CT angiography have
been compared with TOE and found to be an effective alternative
technique to detect peri-device flow.275,276 Device-related thrombus
is seen in 3–7% of patients after LAA closure, and leads to a 3–4 fold
higher risk of stroke.273,274 Factors predicting device-related throm-
bus are previous TIA/stroke, persistent AF, low LVEF, vascular dis-
ease, and early discontinuation of anticoagulation.273,274
If surgical LAA ligation fails or is incomplete, stroke rates are
significantly increased. Similarly, with percutaneous closure devices,
residual LAA leaks were associated with increased risk of thrombo-
embolism in excess of that associated with baseline risk factors or
echocardiogram findings.285
Risk for heart failure incidence and
progression
Atrial fibrillation and HF are conditions that coexist in many patients,
and sometimes it will be difficult to establish if HF was the cause of
AF or AF caused HF (tachycardia-induced cardiomyopathy).287,291 In
the Framingham study, 41% of patients with AF and HF developed
HF first, 38% developed AF first, and in the remaining 21%, AF and
HF occurred at the same time.288 AF is associated with a three-fold
increased risk of incident HF.292 In trials of patients with chronic sys-
tolic heart failure, the prevalence of AF was 4% in patients with Class
I symptoms, 10–27% in patients with Class II–III symptoms, and 50%
for those with Class IV HF symptoms.290 Additionally, aging and the
structural and neurohormonal changes in HF make the development
and progression of AF much more likely. The risks of developing an
AF-induced cardiomyopathy appear to be related to the ventricular
rate during AF and the duration of AF. However, the precise inci-
dence of tachycardia-induced cardiomyopathy with AF, in patients
with and without SHD is unknown.
The mechanisms and pathophysiology of AF and HF share sev-
eral risk factors and common pathophysiologic processes.
Hypertension, smoking, obesity, diabetes, renal impairment, sleep
apnoea, and CAD are all associated with an increased risk of de-
veloping both HF and AF, and each condition increases morbidity
and mortality when associated with the other. All types of HF
(HFpEF or HFrEF) are associated with an increase prevalence of
AF.293,294 There are no studies examining the role of monitoring
to detect AF in asymptomatic patients with HF or the manage-
ment of AF if detected. For patients with cardiac implantable elec-
tronic devices, remote monitoring is a tool for determining AF
burden and is part of routine device follow-up. In patients with
HF, the risk of AF is increased by several mechanisms, remodelling
of atrial structure and increased fibrosis, ectopy promoted by
atrial stretch, increased spontaneous firing in the pulmonary veins
.................................................................................................
Continued
Risk assessment for stroke/
TIA after LAA occlusion/
ligation
Class References
discontinuation of anticoagulation
may be helpful to guide decisions
regarding imaging for device re-
lated thrombus.
Multi-detector CT and cardiac CT
angiography have been found to
be equivalent to TOE to detect
peri-device flow.
275,276
After surgical occlusion or exclusion
of the left atrial appendage, imag-
ing may be useful to look for a re-
sidual appendage and its function
or a residual leak after ligation to
guide decisions regarding
anticoagulation.
277,278,535
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Risk for heart failure incidence
and prognosis
Class References
Screening for AF in patients with HF
should be performed because of
the increased risk of adverse car-
diovascular outcomes in combina-
tion more than the risk conveyed
by either disease state alone.
287,288
Interval use of echocardiography
and arrhythmia directed monitor-
ing for development of AF-in-
duced cardiomyopathy and risk
assessment over time should be
part of standard follow-up for
patients with AF.
289,290
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and alterations in calcium current handling in the atrial muscle and
sarcoplasmic reticulum calcium content.289
The loss of atrial systole in AF impairs LV filling and can result in
left ventricular dilatation, decrease in myocardial blood flow and in-
crease in LV wall stress and end-diastolic pressure. Atrial fibrillation
can decrease cardiac output by 25% particularly in patients with dia-
stolic dysfunction. The mechanisms for reduction in cardiac output
include loss of atrial contribution to ventricular filling, increased mitral
regurgitation and decreased left ventricular filling time. The irregular
and rapid ventricular contraction in AF can lead to LV dysfunction in
an unknown percentage of patients and in some patients a
tachycardia-induced cardiomyopathy results.290 The irregular ven-
tricular response also compromises ventricular performance through
changes in calcium handling and reduced expression of Serca and
phospholamban phosphorylation. Management can vary widely
according to presentation and should be individualized since treat-
ments shown to be effective in one or other condition alone, may
give rise to safety or efficacy issues in an individual patient. Several re-
cent trials have suggested a preferential role for primary catheter ab-
lation of AF in select AF patients with HF compared to medical
therapy alone.295–297 Treatment of AF by either rate or rhythm con-
trol may reverse the cardiomyopathy and improve clinical HF sub-
stantially in selected patients.
Risk for death in atrial fibrillation
patients
Atrial fibrillation is associated with 1.5- to 2-fold higher risk of all-
cause mortality which may result from stroke, HF, or SCD.261 Of the
mortality associated with AF, only 1 in 10 deaths are stroke, and >7
out of 10 are cardiovascular.300 A multipronged strategy incorporat-
ing stroke prevention, better symptom control, and cardiovascular
risk optimization is associated with improved outcomes, including a
reduction in mortality.3,4 Females with AF have slightly higher mortal-
ity compared to male patients. Ethnic or racial differences exist in
mortality risk, with one study showing highest risk in African
Americans among all racial/ethnic groups.301 Also, presence of
comorbidities increases the risk compared with ‘lone’ AF. Advanced
age, renal failure, pulmonary disease, and HF have been found to be
most important risk factors for higher mortality in AF (Figure 5).298,299
Numerous risk scores have been designed to assess the mortality
risk in AF. The CHA2DS2-VASc score was designed to assess stroke
risk, but given it is a cluster of common risk factors for cardiovascular
mortality also predicts mortality risk.302 More complex clinical risk
scores designed to predict mortality, such as an integrated
GARFIELD-AF risk tool, statistically improves mortality prediction,
being superior to the CHA2DS2-VASc score.
303 All clinical risk scores
only have modest predictive value (c-indexes 0.6–0.7) but can always
be statistically improved by the inclusion of cardiac biomarkers, such
as NT-proBNP and hs-TnT. Both biomarkers (and others) have been
found to be independently associated with increased midterm mor-
tality in AF patients presenting to emergency room.304 Indeed, risk
scores incorporating biomarkers have been proposed, such as the
ABC-death risk score, which utilizes age, biomarkers, and clinical his-
tory. The ABC-death score achieved a c-index of 0.74 [95% confi-
dence interval (CI) 0.72–0.76], while the CHA2DS2-VASc score
achieved a c-index of 0.58 (95% CI 0.56–0.61).305 However, the clini-
cal usefulness of any risk-prediction score for mortality has not been
established, and further validation studies are needed. Indeed, many
risk factors or biomarkers are based on measurements done at base-
line, and follow-up events occur many years later. Cardiovascular risk
is not static but changing with increasing age and incident risk fac-
tor(s), thus repeat risk re-assessment is more appropriate given that
a change in risk scores is more highly predictive of adverse outcomes.
Importantly, many biomarkers are non-specific, more likely reflect-
ing a patient with significant comorbidities and significant underlying
heart disease, and are predictive of various endpoints apart from
death, including stroke, heart failure, etc.306,307 Indeed, biomarker-
based scores like ABC-death were derived from a highly selected
clinical trial cohort which was anticoagulated, and values were deter-
mined at study entry (baseline). Many biomarkers also have a diurnal
variation and inter/intra laboratory variability and are predictive of
non-cardiovascular outcomes. Real-world studies investigating the
usefulness of sequential addition of biomarkers have shown limited
value over conventional clinical risk scores.10,308,309 Thus, statistically
significant improved prediction should not be confused with clinically
improved risk prediction. A balance is therefore needed between
(statistically) improved risk prediction and simplicity or practicality
for everyday clinical use in busy clinical settings. In summary, any
novel biomarker (or biomarker-based scores) would need to be vali-
dated in large non-anticoagulated cohorts. This is the starting point of
risk stratification with the newly diagnosed AF patient in any patient
care pathway, and be simple, practical and adequately validated to
.................................................................................................
Risk for death in AF patients
(including risk for SCD)
Class References
Clinical characteristics of the patient
including presence of advanced
age, cognitive dysfunction or de-
mentia, diabetes mellitus, hyper-
tension, prior stroke, vascular.
disease, and HF should be used as
important risk markers of higher
mortality in patients with AF.
298,299
Low Risk
Medium Risk
High Risk
Paents with advanced age, 
heart failure, prior stroke and 
elevated levels of NT-proBNP 
and hs-cTnT
Paents with significant 
comorbidies like hypertension,
diabetes, and  vascular disease
Younger paents without 
structural heart disease or 
significant comorbidies
Figure 5 Mortality risk in patients with atrial fibrillation.
EHRA/HRS/APHRS/LAHRS expert consensus 1148s
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article/22/8/1147/5857108 by M
edicinsk Bibliotek, Aalborg Sygehus SYD
 user on 18 Septem
ber 2020
account for the dynamic nature of risk factors and changes in drug
therapies (including the use of antithrombotic drugs) over time.
Stroke resulting from AF has significant medium-term mortality,
which can be as high as 30.5% at 1 year.310 An 8-point GPS-GF score
utilizing variables including Glasgow Coma Scale, pneumonia, midline
shift on brain images, blood glucose, and female sex has been devel-
oped and was found useful to predict 30-day mortality in patients
with AF-related stroke.311
Spontaneous AF is associated with an increased risk of SCD in
patients with Wolff–Parkinson–White (WPW) syndrome, HCM, and
channelopathies such as Brugada syndrome.261 Several recent studies
on HF and LVH and those on the general population have reported
that AF is linked to an increased risk of SCD.312–314 Mechanisms for
SCD due to AF are well understood for WPW syndrome or HCM,
but are unclear regarding other cardiac disorders. A meta-analysis
demonstrated a significant association between AF and SCD in the
general population as well as in patients with CAD, congestive HF,
HCM, Brugada syndrome, and implanted rhythm devices.315 In a na-
tionwide cohort study from Taiwan, 352 656 patients were identified.
Among AF patients, age >_75 years, congestive heart failure, hyperten-
sion, diabetes mellitus, previous stroke/TIA, vascular diseases,
chronic kidney disease, and chronic obstructive pulmonary disease
were important risk factors for SCD or ventricular arrhythmias.316 A
recent study suggested that optimal pharmacological treatment, in
addition to anticoagulant therapy, can reduce SCD rates in patients
with AF.317 Since pharmacological rhythm control has so far been rel-
atively ineffective in preventing SCD in AF patients with low LVEF,318
catheter ablation may be more appropriate for improving prognosis
in patients with AF.296 To assess the risk of SCD in patients with AF,
recognizing the presence of CAD, HF, LVH/HCM, pre-excitation,
Brugada syndrome, and implanted rhythm devices is crucial.
Examinations including 12-lead ECG, echocardiography, and other
imaging modalities such as cardiac MRI are useful for detecting vari-
ous cardiac disorders. Electrophysiological testing is useful for identi-
fying risks in patients with WPW syndrome and paroxysmal AF.
Risk of adverse outcomes in patients
treated with catheter ablation
Radiofrequency (RF) ablation has emerged as a main therapeu-
tic option for treatment of AF patients since 1998 after the ob-
servation that AF mostly initiates from arrhythmogenic triggers
in muscular sleeves in the pulmonary veins.326 There is abun-
dant evidence that AF ablation is an effective method for AF
suppression leading to significant reduction of AF episodes and
burden accompanied by substantial improvement in symptoms
and quality of life if performed in symptomatic patients. For this
reason, AF ablation is mainly recommended by current guide-
lines as a method for symptom improvement in symptomatic
AF patients.261
Post-ablation atrial fibrillation recurrence
Post-ablation AF recurrence is one of the most important and fre-
quent adverse outcomes, which occurs in 30–50% of cases.327,328 In
fact, although the acute success rate of AF catheter ablation seems
high, achieving a durable treatment efficacy has remained a main chal-
lenge.261,328 Different factors including female gender, older age, tra-
ditional cardiac risk factors, left ventricular dysfunction, increased
epicardial adipose tissue, myocardial fibrosis, and atrial enlargement
have been proposed as possible predictors of post-ablation AF recur-
rence.329–331 Moreover, diverse AF recurrence risk-prediction
scores, including APPLE, ALARMEc, ATLAS, BASE-AF2, CAAP-AF,
DR-FLASH, and MB-LATER have been introduced; however, their in-
tegration into the daily clinical practice needs further support by
healthcare systems.332–341
Other adverse outcomes
Apart from AF recurrence, according to the available real-world
data, around 5–15% of patients undergoing AF catheter ablation ex-
perience complications, mainly during the index hospitalization and
early in the post-procedure course.319–324 A variety of complications,
including neurological, gastrointestinal, cardiovascular, vascular and
peripheral, as well as pulmonary complications have been reported
to occur after ablation procedures.319–324,342–346 Although different
modifiable factors such as metabolic syndrome, hypertension, alcohol
consumption, sleep apnoea, and obesity have been proposed to be
related with arrhythmia-free survival after catheter ablation,347–350
their impact on the ablation adverse outcomes is not clear yet, and
requires further investigations.
Mortality and morbidity
The impact of the ablation on hard clinical endpoints is much less evi-
dent. Previous findings from observational studies indicated a positive
effect of the procedure on mortality and morbidity.351 These, how-
ever, were not confirmed in the recent large randomized Catheter
Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial
(CABANA) that had as primary endpoint a composite of death, dis-
abling stroke, serious bleeding, or cardiac arrest.295 In contrast, posi-
tive effects on hard clinical endpoints including mortality have been
reported in patients with HF. In the CASTLE-AF trial, patients with
impaired LVEF <35% and previous ICD implantation who were
treated with ablation therapy had a lower rate of death from any
cause or hospitalization for worsening HF compared to patients un-
dergoing medical treatment.296
.................................................................................................
Risk of adverse outcomes in patients
treated with catheter ablation
Class References
Patients that undergo an AF ablation should
be monitored closely in the first 30 days
after the procedure due to a higher risk
of neurological, gastrointestinal, cardio-
vascular, vascular and peripheral
complications.
319–324
Wolff–Parkinson–White syndrome patients
following radiofrequency ablation may
benefit from additional follow-up due to
a persistent elevated risk of developing
AF compared to the general population.
295,325
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Stroke
Regarding the impact of AF ablation on stroke and in particular the
validity of stroke risk schemes for stroke risk stratification after abla-
tion, observational data suggest a reduced stroke risk after AF abla-
tion and a possibly safe termination of anticoagulation, at least in
selected patients.352,353 Conclusive evidence is expected from ongo-
ing randomized trials as the Optimal Anticoagulation for Higher Risk
Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)
(NCT02168829) and the Prevention of Silent Cerebral
Thromboembolism by Oral Anticoagulation with Dabigatran After
Pulmonary Vein Isolation for Atrial Fibrillation (ODIn-AF) trial
(NCT02067182). Until now, one randomized trial showed that abla-
tion therapy for AF in patients with impaired LVEF was associated
with significantly lower rate of death from any cause and worsening
HF.274 Subgroup recommendations may change after the completion
of trials studying the effect of ablation on stroke and the need for anti-
coagulation. Particularly in HF patients, it remains to be seen in which
subgroups of patients the data indicating mortality reduction after AF
ablation are applicable.
Catheter ablation in Wolff–Parkinson–White patients
Careful attention must be given in WPW patients who underwent
RF ablation, as it was demonstrated that they had an increased risk of
AF at follow-up when compared to general population, though an in-
creased risk of death was not reported.296,325
Risk of adverse outcomes in patients
treated with surgical Maze
The surgical Cox–Maze operation was introduced in 1987 to treat
patients with refractory AF.354 This surgical approach carries more
risk of complications than the catheter ablation procedure, and is
suitable for selected patients only. In this setting, we can observe
three different case-scenarios.
Atrial fibrillation surgery
A simplification of the Cox–Maze procedure was proposed by
replacing the ‘cut and sew’ lesions by different ablation devices and
minimally invasive access.355 In the recent years, bipolar RF clamping
devices guided on a beating heart, by thoracoscopic epicardial
approaches have been introduced.277,356 This evolution has allowed
the implementation of this surgery for stand-alone persistent and
long-standing persistent AF ablation, after an ineffective antiarrhyth-
mic drug treatment or a previous endocardial ablation failure with a
IIa (Level of Evidence B) indication.278 On another hand, this invasive
approach carries some potential risks that need to be anticipated and
discussed. Ideally, this step should involve an arrhythmia team in or-
der to discuss the risk–benefit balance of the procedure on a case by
case basis.357
Surgical Maze in patients with concomitant heart surgery
An AF surgical ablation procedure is reasonable for selected patients
with AF undergoing cardiac surgery for other indications.261 In
patients that may receive a concomitant Maze procedure, a shared
decision-making strategy should be used with an AF heart team to
make the best decision available for the patient and their heart
condition.357 Mortality or major morbidity was not affected by con-
comitant AF surgery [adjusted odds ratio (OR) 1.00; 95% CI 0.83–
1.20], but pacemaker implantation was more frequent (adjusted OR
1.26; 95% CI 1.07–1.49).358 Stiff LA syndrome was also reported after
surgical Maze procedure, presenting with dyspnoea, pulmonary hy-
pertension, and elevated left ventricular end-diastolic pressure attrib-
uted to reduced LA compliance.359
Predictors of AF recurrence after surgery include left atrial dilata-
tion, older age, over 10-year history of AF, and non-paroxysmal
AF.360–364
Stand-alone surgical Maze
A stand-alone AF surgical ablation procedure may be reasonable for
selected patients with highly symptomatic AF not well managed with
other approaches (e.g. after a failed catheter ablation, longstanding
AF, dilated left atrium).365 After Cox–Maze IV stand-alone proce-
dure, overall operatory mortality was 1–1.8%, overall complication
rate was 10%, 8% required pacemaker placement, and 12-month
freedom from atrial tachyarrhythmias was 89% (78% without antiar-
rhythmic drugs).366,367
Left atrial appendage exclusion or removal during
surgical Maze
The prospective randomized trial comparing the efficacy and safety
of LAA exclusion or removal with surgical Maze procedure is lacking.
However, epicardial LAA Atriclip occlusion showed a high rate of
complete left atrial appendage occlusion and reduces the incidence
of stroke in patients with AF undergoing cardiac surgery.281 After sur-
gical occlusion or exclusion of the LAA, it is recommended to con-
tinue anticoagulation in at-risk patients with AF for stroke
prevention.261 If surgical LAA ligation fails or is incomplete, stroke
rates are significantly increased compared to patients with complete
closure.285
How to assess risk for ventricular
tachyarrhythmia in specific
populations
Patients with ischaemic heart disease
Ventricular tachyarrhythmia/ventricular fibrillation events are closely
related to the risk of SCD in patients with ICM. For this reason, the
risk of VT/VF is commonly used as a surrogate for the risk of SCD. In
addition, in ICM, myocardial ischaemia is the most common trigger
for VF and SCD.
For primary prevention, our current approach to SCD risk stratifi-
cation relies mainly on the evaluation of LVEF: values below 30–35%
allow the identification of ICD candidates, who are at highest relative
risk of SCD. On the other hand, patients with a LVEF >35% account
for the highest absolute number of SCDs.368 For this reason, many
researchers emphasize that EF is an inadequate marker for detecting
patients who are at high risk for SCD despite having a normal or sub-
normal EF. It seems also to have very limited value to identify
amongst patients with a low LVEF those who will benefit the most
from an ICD. In other words, many patients with EF <_35% are
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unnecessarily implanted with an ICD for primary prevention, while
some others, having a EF >35% and a high risk of VT/VF, are not pro-
tected. In this setting, new markers are needed to optimize screening
and patient selection for ICD implantation. For secondary preven-
tion, SCD risk is significantly higher, and risk stratification is certainly
more standardized.61,74
Secondary prevention of ventricular tachyarrhythmia/
ventricular fibrillation in patients with ICM
For more than 20 years, patients with a history of sustained VT/VF
have been recognized to be at high risk of recurrence.370 Nowadays,
these patients are given a Class I (Level of Evidence A) indication for
ICD implantation.70 For this reason, the practical usefulness of VT/VF
recurrence risk assessment is questionable, as additional testing is
likely not going to influence decision pathways (i.e. catheter ablation
or antiarrhythmic drug therapy as an alternative to ICD implantation),
and patient outcomes in a secondary prevention setting.
Primary prevention of ventricular tachyarrhythmia/
ventricular fibrillation in patients with ICM and a left
ventricular ejection fraction 35%
Patients presenting with ICM, in NYHA Class II–III, with EF <_35% af-
ter 3 months of optimized heart failure pharmacological treatment,
are given a Class I/A indication for ICD implantation for the primary
prevention of SCD.70 Nonetheless, it is widely recognized that only a
small subgroup of these patients will present with VT/VF during
follow-up, and consequently will benefit from the device. A better
risk stratification of these patients would be crucial to help identify
those who would indeed benefit from an ICD. Most of the numerous
investigations assessed in this setting, like programmed ventricular
stimulation (PVS), heart rate variability (HRV), late ventricular poten-
tials (LVP), baroreflex sensitivity, QT interval dispersion, T-wave
alternans, and heart rate turbulence have been largely abandoned be-
cause none of them have influenced routine clinical prac-
tice.46,73,371,372 However, some of these explorations, like T-wave
alternans, have shown some value for SCD prediction in ICM
patients.42 It is still uncertain whether biochemical markers as B-type
natriuretic peptide and N-terminal pro-BNP will prove useful in
assessing risk for VT/VF. Cardiac MRI with LGE should also help to
improve VT/VF and SCD risk stratification by analysing cardiac struc-
ture and myocardial scarring.375 Finally, a recent randomized trial sug-
gests that assessment for hibernating myocardium performed
routinely is of no use to decrease the risk of SCD.68
Primary prevention of ventricular tachyarrhythmia/
ventricular fibrillation in patients with ICM and left
ventricular ejection fraction 35%
.................................................................................................
Secondary prevention of VT/VF in
patients with ICM
Class References
ICM substrate and ischaemic triggers for
VT/VF must be evaluated when appropri-
ate (coronary angiogram, functional
ischaemic evaluation by nuclear scan,
stress-echocardiography, or MRI).
54,70,71
Cardiac MRI with a LGE can be considered
in order to evaluate arrhythmogenic sub-
strate including myocardial scarring to in-
clude in risk assessment, and guide a
possible VT ablation procedure. This in-
vestigation should be preferably per-
formed before ICD implantation to avoid
artefacts due to the presence of an
implanted device.
369
.................................................................................................
Primary prevention of VT/VF in
patients with ICM and LVEF35%
Class References
ICM substrate and ischaemic triggers for
VT/VF must be evaluated when appropri-
ate (coronary angiogram, functional
ischaemic evaluation by nuclear scan,
stress-echocardiography or MRI).
54,70,71
Cardiac MRI with a LGE can be considered
in order to evaluate arrhythmogenic
369
Continued
.................................................................................................
Continued
Primary prevention of VT/VF in
patients with ICM and LVEF35%
Class References
substrate including myocardial scarring to
include in risk assessment and guide a
possible VT ablation procedure. This in-
vestigation should be preferably per-
formed before ICD implantation to avoid
artefacts due to the presence of an
implanted device.
.................................................................................................
Primary prevention of VT/VF
in patients with ICM and
LVEF > 35%
Class References
ICM substrate and ischaemic triggers
for VT/VF must be evaluated
when appropriate (coronary an-
giogram, functional ischaemic
evaluation by nuclear scan, stress-
echocardiography or MRI).
54,70,71
EPS and non-sustained VT evalua-
tion could be considered to
311,373,374
Continued
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This group of patients should be the priority for VT/VF risk as-
sessment: in absolute numbers, it represents by far the highest
number of those at risk of VT/VF and SCD.368 In addition, these
patients are currently non-protected, as they are not targeted for
ICD implantation in guidelines, due to their LVEF value.70 In this
setting, MRI with LGE could be an option to better understand
the diagnosis, prediction, and treatment of VT/VF.369 This investiga-
tion could possibly help improve VT/VF and SCD risk stratification
by analysing cardiac structure and myocardial scarring, particularly
when EF is relatively preserved. In this setting, a large prospective
trial documenting that treatment guided by MRI-based risk stratifi-
cation improves outcomes in this patient group is still very much
expected.375
Otherwise, the MUSTT Trial suggested the value of EPS for im-
proving the SCD risk stratification, in the subgroup of ICM patients
with a residual EF comprised between 30 and 40%.376
In addition, other non-invasive investigations like tissue
Doppler Imaging (TDI) seem also to be of potential value in pre-
dicting VT/VF in ICM. Late diastolic velocity assessed by TDI,
particularly when detected in the inferior myocardial wall, seems
to be a sensitive marker of future VT/VF.373 Finally, it is well
known that non-sustained ventricular tachycardia (NSVT) is a
marker of increased risk of VT/VF and arrhythmic death. During
the convalescent phase after an acute coronary syndrome,
NSVT seems to be associated with an increased risk of cardio-
vascular death, most marked within the first 2 months after de-
tection.374 The use of such investigations could help to detect
those patients at higher risk of VT/VF, more particularly during
the early phase after an acute coronary event. Specific measures
like prolonged monitoring or use of wearable cardiac defibrilla-
tor could be undertaken on an individual patient-case basis.
However, more solid data are needed to support such recom-
mendations broadly.
Patients with non-ischaemic heart failure
Patients with non-ischaemic HF represent a broad and diverse
group of patients including those with progressive and infiltrative
forms of cardiomyopathies. For this reason, the risk of develop-
ing VT in non-ischaemic HF is difficult to accurately predict in
this group of patients. Subsequent sections in this document
will address specific conditions that have unique risk profiles in-
cluding inflammatory cardiomyopathies, congenital heart disease,
ACM, and Chagas’ disease.
Prior investigations into identification of the risk of developing VT
in non-ICM focused on the risk of SCD and the role of the implanted
defibrillator for primary prevention. The DANISH trial61 reported no
survival benefit from prophylactic ICD implantation in the overall
cohort. Implantable cardioverter-defibrillator reduced SCD to half,
and subgroup analysis showed that in patients younger than 68 years,
survival was prolonged with an ICD. Although pooled analysis of the
five primary prevention trials (DEFINITE, SCD-HeFT, CAT,
AMIOVIRT, COMPANION, and DANISH; n = 2970) revealed that
ICD therapy was superior to medical therapy in patients with non-
ICM with decreased cardiac function, these trials were judged
globally negative.378
In a limited number of studies outside of these clinical trials, the
role of EPS or non-invasive programmed stimulation has revealed in-
consistent results.377 More recently, the role of cardiac MRI for defi-
nition of scar and potential substrate has emerged as a powerful risk
stratification tool in observational studies.49,379,380 Genetic testing is
also useful in patients with decreased cardiac function with conduc-
tion disturbance (i.e. LMNA mutations).
In summary, non-ischaemic HF includes a diverse group of patients
with reduced ventricular function due to cardiomyopathies from dif-
ferent aetiologies, and at high risk for VT. Reduced cardiac function
remains a powerful predictor of VT and appropriate ICD therapy in
these patients as a primary prevention. Cardiac MRI and EP testing
shows promise in some subsets. Further characterization based on
.................................................................................................
Continued
Primary prevention of VT/VF
in patients with ICM and
LVEF > 35%
Class References
improve VT/VF risk stratification
in patients with relatively pre-
served LVEF, particularly in the
convalescent phase (first 2
months) after an acute coronary
syndrome.
Heart rate variability (HRV), LVP,
baroreflex sensitivity, QT-interval
dispersion, T-wave alternans and
heart rate turbulence have not
been evaluated adequately in this
population for generalized use.
73,371,372
.................................................................................................
Patients with non-ischaemic
heart failure
Class References
MRI may be considered for further
risk stratification of sudden death
in patients with non-ICM who do
not otherwise meet an indication
for ICD implantation.
377
EPS may be considered for further
risk stratification of sudden death
in selected patients with non-ICM
who do not otherwise meet an
indication for ICD implantation.
377
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the type of cardiomyopathy leading to HF shows the most promise
for accurate assessment of VT risk.
Patients with inflammatory
cardiomyopathies
Inflammatory cardiomyopathies encompass a broad spectrum of dis-
orders characterized by myocardial inflammation as the primary
cause of cardiac dysfunction. This includes viral myocarditis (com-
monest cause), cardiac sarcoidosis, giant cell myocarditis, autoim-
mune myocarditis associated with underlying connective tissue
diseases, eosinophilic cardiomyopathies, and Chagas disease
(addressed in a separate chapter).
In patients who present with ventricular arrhythmias and diagnosed
with non-ICM, the incidence of inflammatory cardiomyopathy may be
as high as 50%.381 Therefore, it is important to consider inflammatory
cardiomyopathies as an underlying cause, given that these conditions
may benefit from specific aetiology-driven treatments. Infectious
causes of myocarditis include viral (e.g. parvovirus B19 and human
herpes virus 6 genomes that predominate in inflammatory
cardiomyopathies, other cardiotropic viruses include enteroviruses,
adenoviruses, hepatitis C, and human immunodeficiency viruses) and
uncommonly bacterial and other causes depending on the
geographical area and immunosuppression status. Myocarditis
associated with connective tissue and autoimmune diseases
encompass systemic lupus erythematosus, scleroderma, rheumatoid
arthritis, dermatomyositis, polymyositis, cardiac sarcoidosis and giant
cell myocarditis. Drug reactions may also cause hypersensitivity
myocarditis.381,382 In cases of an established cause of inflammatory
cardiomyopathy, the focus should be on treating the underlying
inflammatory condition. In the case of cardiac sarcoidosis,
retrospective series have shown that specific treatment with
immunosuppressive therapy can increase VT free survival.52
Cardiac MRI scan is the gold standard for diagnosing myocarditis
and inflammatory cardiomyopathies. Oedema, hyperaemia, and LGE
form the diagnosis of acute myocarditis. Further diagnostic informa-
tion is gleaned from T1 and T2 mapping techniques. Although no spe-
cific LGE pattern on MRI is diagnostic of cardiac sarcoidosis, LGE is
most often observed in basal segments, particularly of the septum
and lateral wall, and usually in the mid-myocardium and epicardium
of the myocardium383–385
The presence of LGE is significantly associated with increased risk
of adverse cardiac events. The presence of LGE on cardiac MRI was
associated with increased risk of ventricular arrhythmias and death
by greater than 20 fold in patients with EF >35% and extracardiac sar-
coidosis compared to sarcoid patients without evidence of LGE on
MRI, and the burden of LGE was associated with higher rates of
death/VT.386 In a meta-analysis of 155 patients with systemic sarcoid-
osis who underwent cardiac MRI for work-up of cardiac sarcoidosis,
the presence of LGE was associated with hazard ratio of 31.6 for
death, aborted SCD, or appropriate ICD discharge and provided su-
perior prognostic information as to compared to other clinical and
functional characteristics, including LVEF.51
In addition, the distribution of LGE confers important prognostic
information, with mid-wall anteroseptal LGE representing a more
malignant form compared to a sub-epicardial inferolateral wall LGE
pattern.387,388 Inflammatory biomarkers, such as C-reactive protein,
are typically lower in this group with septal LGE, but biomarkers of
myocardial damage such as troponin are typically higher, suggestive
of a subset with less inflammation but greater myocardial injury. F-flu-
orodeoxyglucose (FDG)-PET is advantageous for detecting active in-
flammation in cardiac sarcoidosis, and a mismatch of FDG and
perfusion and involvement of the right ventricle predicts adverse
cardiac events and ventricular arrhythmias, respectively.53
Endomyocardial biopsy is performed in cases where a histological di-
agnosis is required to confirm cardiac sarcoidosis or giant cell myo-
carditis, with its yield enhanced by electrogram guidance. Active viral
genomes may also be identified by biopsy, which can differ signifi-
cantly from peripheral serological tests.382,389
Little data exist on how to assess risk of VT/VF in inflammatory
cardiomyopathies. Besides EF, which is used for all non-ischaemic
aetiologies, no randomized studies have evaluated other parameters
or even EF as a predictor of VT in different inflammatory cardiomy-
opathies. In particular, certain inflammatory cardiomyopathies may
carry higher risk than others (sarcoidosis vs. viral myocarditis). Risk of
ICD therapy may be as high as 15% per year in biopsy proven cardiac
sarcoidosis patients.390 Although randomized data on use of higher
EF in these patient populations is lacking, given risk of VT noted in ret-
rospective studies, use of MRI and cardiac PET to evaluate aetiology
of non-ischaemic heart disease is warranted, and treatment of inflam-
mation to reduce risk of VT is advised. Furthermore, cardiac PET and
MRI can be used to assess for recurrent inflammation or progression
of disease on treatment.
Patients with congenital heart disease
.................................................................................................
Patients with inflammatory
cardiomyopathies
Class References
In patients with non-ischaemic heart dis-
ease who present with ventricular
arrhythmias, use of cardiac MRI or
cardiac PET can help delineate aetiol-
ogy of non-ICM, initiate aetiology-
driven treatment, and evaluate
prognosis.
52,53,379
.................................................................................................
Risk for ventricular arrhythmias in
patients with congenital heart
disease
Class References
In the paediatric patient with CHD, ven-
tricular overload, surgical scars and
patches or baffles, ventricular dysfunc-
tion, and previous conduction defects
are recognized risk factors for VT.
391–393
Continued
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Ventricular arrhythmias in patients with congenital heart disease
(CHD) may be observed in two different groups: the paediatric age
group and adults with repaired congenital defects group.397 In the
paediatric age, life-threatening VT is rare both prior to and after sur-
gery. Ventricular tachyarrhythmia is seen in only 1.8% of children un-
dergoing an EPS,391 is usually associated with structurally normal
heart and most frequently comes from the right outflow tract and
left outflow tract and sinuses of Valsalva.
In paediatric patients with CHD, the haemodynamic and electro-
physiologic factors related to each disease state and associated thera-
peutic interventions play an important role in the development of
VT, with ventricular overload, surgical scars and patches, baffles and
conducts, ventricular dysfunction, and previous conduction defects
among the most relevant.392 In the early post-operative stage, Van
Hare et al. reported only 3 patients with VT out of 580 undergoing
paediatric surgery and the most important risk factor was the surgical
procedure.391 Sustained VT may arise in the setting of myocardial is-
chaemia or infarction and may be facilitated by disruption of the ven-
tricular myocardium caused by scar due to ventriculotomy, fibrotic
tissue, or ventricular dilatation.393
In adult patients with CHD, VTs are mainly observed after correc-
tion of tetralogy of Fallot (TOF) and left ventricular outflow tract
defects but may also arise in other defects as transposition of the
great arteries with atrial switch, univentricular hearts, double-outlet
RV, and ventricular septal defects. Older age at surgery, poor haemo-
dynamic status, and prolongation of the QRS represent the most
common risk factors. In patients with TOF, the correlation of residual
haemodynamic lesions and right ventricular dysfunction with risk of
VT or SCD has been extensively established.394,395 Potentially
treatable residual haemodynamic problems, pulmonary hyperten-
sion, elevated end-diastolic pressures, and reduced ventricular func-
tion should be treated as part of the arrhythmia management.
Particularly in this group, frequent PVCs, QRS 180 ms or more, pallia-
tive systemic to pulmonary shunts, syncope, atrial tachycardia, de-
creased LVEF, dilated right ventricle, severe pulmonary stenosis or
regurgitation are risk factors for sustained VT, and inducible sustained
VT correlates with increased risk of SCD.396,398 EPS might be consid-
ered for risk assessment of VT/VF in this group of patients with high-
risk clinical characteristics and frequent ventricular arrhythmias.327
Patients with inherited arrhythmia
diseases (inherited channelopathies and
inherited structural diseases including
arrhythmogenic right ventricular
cardiomyopathy)
Patients with inherited arrhythmia disease are without doubt at in-
creased risk for ventricular arrhythmias, including SCD. The extent
to which this is pertinent and predictable is different for the various
conditions.
The main primary inherited arrhythmia syndromes, i.e. the ‘chan-
nelopathies’ are LQTS, Brugada syndrome and CPVT.400 Patients
that are symptomatic (syncope, cardiac arrest) at the time of presen-
tation are at highest risk, with arrhythmic syncope representing a sen-
tinel sign of risk, and resuscitated cardiac arrest reflecting the highest
risk cohort.97 Despite major social impact on perceived risk, family
history is not of major importance in all three diseases.
In LQTS, clearly defined disease-specific risk factors are the extent
of resting QT prolongation, documentation of arrhythmias and gene
and even mutation specific associated risk.401 In CPVT, the extent of
the arrhythmic response of an exercise test predicts events, including
breakthrough symptoms on therapy.402 It follows that risk assess-
ment requires a baseline ECG and an exercise test in both conditions,
with potential value of ambulatory monitoring. Assessment should
.................................................................................................
Continued
Risk for ventricular arrhythmias in
patients with congenital heart
disease
Class References
In adult patients with CHD, older age at
surgery, poor haemodynamic status,
and prolonged QRS represent the most
common risk factors for ventricular
arrhythmias.
392–394
In adult patients with CHD, VTs are
mainly observed after correction of te-
tralogy of Fallot (TOF) and left ventric-
ular outflow tract defects.
394–396
In patients with TOF, residual haemody-
namic lesions and ventricular dysfunc-
tion represent the most important risk
factors for VT or SCD.
394–396
In patients with TOF, frequent PVCs, QRS
>180 ms, palliative systemic to pulmo-
nary shunts, syncope, atrial tachycardia,
decreased LVEF, dilated right ventricle,
severe pulmonary stenosis or regurgita-
tion, are risk factors for sustained VT.
394–396
.................................................................................................
Risk for ventricular arrhyth-
mias in patients with inherited
arrhythmia diseases
Class References
Patients with primary inherited ar-
rhythmia syndromes and cardio-
myopathies should undergo risk
stratification that integrates clini-
cal presentation, family history,
and non-invasive diagnostic
testing.
399
Select patients with primary inher-
ited arrhythmia syndromes and
cardiomyopathies may benefit
from electrophysiologic testing to
refine non-invasive risk
stratification.
536
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include asymptomatic patients often identified during family screening
or after incidental unrelated medical evaluation.
In Brugada syndrome, there is uncontested agreement that symp-
tomatic patients (arrhythmic syncope, cardiac arrest) are at high risk
for SCD, requiring aggressive therapy with an ICD in most circum-
stances. Risk stratification in asymptomatic individuals with a sponta-
neous type 1 ECG is much less clear, involving a variety of ECG
characteristics and potential value of programmed electrical stimula-
tion (PES).403,404 ECG parameters that have been associated with in-
creased risk include QRS fragmentation, early repolarization,
Brugada type changes in non-anterior precordial leads and a positive
signal-averaged ECG. Programmed electrical stimulation with a non-
aggressive stimulation protocol may be of importance, although the
risk of an inducible patient is only marginally different from a non-
inducible patient.77 In LQTS, CPVT, and Early Repolarization syn-
drome, PES is of no importance. The presence of a SCN5a mutation
may contribute to risk in Brugada syndrome.405 Early repolarization
syndrome, short-coupled idiopathic VF (SCIVF), and SQTS are un-
common causes of cardiac arrest and sudden death. Though the early
repolarization pattern conveys a small increase in risk, the only
patients where the risk is substantive to consider intervention are
those with prior cardiac arrest or syncope with a positive family his-
tory. There are no validated risk models in SQTS and SCIVF.
In the cardiomyopathies, i.e. the secondary inherited arrhythmia
syndromes, risk stratification is also disease specific. In hypertrophic
cardiomyopathy (HCM) septal thickness, the hallmark of the disease
is an important contributor to risk. Other risk factors include left
atrial dimension, left ventricular outflow tract gradient (all echocar-
diographic parameters), the presence of ventricular arrhythmias on
ambulatory monitoring (Holter) or documentation otherwise, symp-
toms (i.e. unexplained syncope, palpitations associated with near syn-
cope), demographic factors (age in particular), and family history. All
these factors are included in the ESC risk score calculator,406 which is
readily available in an online tool (http://www.doc2do.com/hcm/
webHCM.html), and applied after standard imaging, exercise testing
and ambulatory monitoring. Validation of the ESC risk calculator is
not compelling, and consideration of imaging and exercise blood
pressure response parameters have also been used in borderline
cases. In inherited, i.e. non-ischaemic, dilated cardiomyopathy
(DCM), the genetic background is very important, with LMNA
(Lamin A/C) and PLN (Phospolamban) leading to highly arrhythmic
substrates.123,407,408 Of course, reduced LVEF and the presence of
ventricular arrhythmias during ambulatory monitoring are important
risk factors as well. In arrhythmogenic right ventricular cardiomyopa-
thy (ARVC or ACM), symptomatic arrhythmic events identify the pa-
tient at highest risk, and major risk factors include age, male sex,
unexplained syncope, non-sustained VT, number of anterior precor-
dial leads with T wave inversion, and severe right or left ventricular
dysfunction.409 Hence, as for the other cardiomyopathies, echocar-
diographic imaging, and Holter monitoring is required for risk assess-
ment. In all cardiomyopathies, MRI is becoming increasingly
important, in particular to show the presence of fibrosis (HCM,
DCM, ACM) and assess left and right ventricular function. Genetic
testing should be considered in any patient with a phenotype suggest-
ing an inherited cardiomyopathy and in DCM with a suggestive family
history or onset at an early age that is otherwise unexplained (i.e. not
myocarditis, sarcoidosis etc.). Genetic testing is largely for diagnosis,
and only informs risk when a high-risk form of cardiomyopathy is di-
agnosed, such as PLN or LMNA.
Risk stratification in patients with ACM,
specified for arrhythmogenic right
ventricular cardiomyopathy
In arrhythmogenic right ventricular cardiomyopathy (ARVC or ACM),
the most important features characterized as the high arrhythmic risk
include the electric instability (i.e. sustained ventricular arrhythmia
[VA]), genotype-positive, extent of structural involvement, cardiac
syncope, the presence of multiple mutations, and the history of com-
petitive or endurance exercise.410,411 In patients without prior VA, an
available online prediction model, derived from the largest cohort of
ARVC patients, using readily available clinical parameters was devised
to estimate the risk of VA and to guide the decisions of ICD implanta-
tion as primary prevention (www.arvcrisk.com).415
There is a dose-dependent relationship between endurance exer-
cise and the disease onset and progression in confirmed ARVC
patients. Exercise restriction is recommended to prevent disease
progression and SCD in confirmed ARVC patients with ICD412 and
genotype-positive relatives.413 In general, high-level or endurance ex-
ercise is not recommended in confirmed ARVC patients or at risk.
Ambulatory ECG monitoring is crucial to detect the PVCs burden
or the presence of non-sustained VT, which also provide prognostic
.................................................................................................
Risk stratification of ventricular
arrhythmias in ARVC
Class References
In patients with ARVC, history of
aborted sudden death, sustained ven-
tricular arrhythmias, and severe right
and/or left ventricular dysfunction
identify a high risk of cardiac death.
410,411
In patients with ARVC, advice to not
perform high-level or endurance ex-
ercise should be given.
412,413
Clinical factors including age, male sex,
unexplained syncope, non-sustained
VT, number of anterior precordial
leads with T wave inversion, and ge-
netic mutation status can be used for
prognostic stratification of patients
with ARVC.
410,411
In patients with confirmed ARVC, regu-
lar Holter monitoring and imaging for
assessment of ventricular function
may be useful.
412,413
A detailed history of exercise intensity
and duration may be helpful in
patients with ARVC as exercise level
may represent a modified risk factor
of adverse cardiovascular events and
disease progression.
414
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information in ARVC.414 All positive criteria of signal-averaged ECG
non-invasively identifies the slow conduction of myocardium and has
been proven for risk stratification in patients with suspicion or con-
firmed ARVC.416
Echocardiography and cardiac MRI provide accurate measure-
ments of right ventricular global and regional dysfunction and right
ventricular volume and regional/global ventricular function, as the im-
portant variable for assessment of right and left ventricular disease.
The Task Force Criteria did not include cardiac MRI measures of right
ventricular myocardial fat or LGE in order to risk stratify the
ARVC.417 In summary, abnormal cardiac MRI was an independent
predictor of clinical events with a cumulative effect of the abnormali-
ties including morphology, wall motion, and fat/fibrosis in ARVC
patients.416
An EPS may provide help distinguish ARVC from idiopathic right
ventricular outflow tract (RVOT) VT. Additionally, positive inducibil-
ity on program ventricular simulation is not a perfect surrogate
marker neither for ARVC diagnosis, nor the decision of ICD implan-
tation.410,411 EPS may be beneficial to identity patients that may bene-
fit from ablation. In this setting, EPS with high-dose isoproterenol
may help differentiate patients with idiopathic VT or ventricular pre-
mature beats from those with ARVC.418 The positive inducibility of
EPS can predict any ICD therapy, including VF, and can be an impor-
tant parameter for risk stratification in patients with ARVC.
ARVC is considered to have desmosome dysfunction. Genetic
causes of isolated or predominantly RV arrhythmia and structural ab-
normalities are most commonly associated with desmosomal gene
variants. Positive genetic test contributes up to 50% of the diagnosis
of ARVC, however, in confirmed ARVC patients, limited evidence of
clinical actionable risk stratification or use of management of disease.
Several gene variants have been reported in patients with left ventric-
ular or biventricular arrhythmia. Left ventricular dysfunction is most
often present in patients with ARVC with pathogenic variants in
Lamin A/C, or variants in the PLN and TMEM43 genes, and followed
by variants in DSP, DSG2/DSC2.123,399,419,420
Patients with Chagas’s disease
Chagas disease is an infectious disease affecting 10 million people
around the world and 100 million more are at risk of this infection.
Due to migration, it is estimated 750 000 infected carriers live in the
USA or Europe.531,532 VA, especially sustained VT is closely related
to high mortality, sudden death (SCD) happening in 17–50% of
chronically ill patients.533 Based on the identification of different risk
factors, Rassi et al. developed a mortality risk score (Table 3).523
Patients with HF, NYHA Class III/IV and NSVT on Holter and
patients in NYHA Class I/II, with left ventricular dysfunction and
NSVT on Holter are at the highest risk of death and should be
regarded as candidates for aggressive therapeutic management.
Conversely, patients with an abnormal ECG (right or left bundle
branch conduction disorders) but in NYHA Class I/II HF without left
ventricular dysfunction or NSVT on Holter are at lower risk of death.
These patients should be followed up annually or biannually.
Between these two extremes, some patients are at intermediate risk
and their treatment strategies should be individualized.
Sustained VT has been reported as the main cause of syncope in
patients with non-documented recurrent syncope and bundle branch
block (BBB). In these cases, an EPS has been recommended for diag-
nosis elucidation.525 A finding of scar by LGE by cardiac MRI in
patients with Chagas disease is considered a strong predictor of a
combination of sustained VT and death.534
How to assess risk for
adverse outcomes in
patients with ventricular
tachyarrhythmia
Risk for appropriate and inappropriate
implantable cardioverter-defibrillator
therapies
ICD therapies are associated with an increase in mortality.370,422–424
A single ICD shock is associated with a two- to five-fold increase in
mortality, and progressive heart failure has been reported the most
.................................................................................................
Patients with Chagas’ disease Class References
The Rassi score is useful in assessing
risk of death in Chagas’ disease
patients.
523,524
In patients with syncope and a BBB,
an invasive EPS is useful in assess-
ing risk of sustained ventricular
arrhythmias.
525,526
When available, cardiac MRI with
LGE should be considered to
evaluate for arrhythmogenic sub-
strate as part of a risk stratifica-
tion strategy in those patients
with cardiomyopathy.
527–530
.................................................................................................
Table 3 Rassi score
Risk factor Points
NYHA Classes III or IV 5
Cardiomegaly (chest radiograph) 5
Segmental or global wall motion abnormality
(2D echocardiogram)
3
Non-sustained ventricular tachycardia (24-h Holter) 3
Low QRS voltage (ECG) 2
Male sex 2
Total points Total mortality (%) Risk
5 years 10 years
0–6 2 10 Low
7–11 18 44 Intermediate
12–20 63 84 High
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common cause of mortality among these patients.425–427 ICD thera-
pies are classified as appropriate, inappropriate, avoidable, and phan-
tom.370,428,429 Approximately 12–17% of patients receive
inappropriate ICD shocks.422,425–427 Both appropriate and inappro-
priate shocks area associated with an increase in mortality and can
significantly lower quality of life. Thus, identifying predictors of ICD
therapies may improve quality of life and long-term outcomes in
patients with ICDs.
Appropriate shock predictors
A previous episode of sustained VT correlates with high rate of ap-
propriate shocks.430–433 A higher risk of appropriate therapy was
seen in a secondary prevention ICD group when compared with a
primary prevention ICD group at 5-year follow-up, while the rate of
inappropriate therapy was comparable.434 Several studies have
shown male sex as an independent risk factor for appropriate ICD
therapies.435 Women are 30–50% less likely to receive an appropri-
ate shock,436–439 and this difference is more pronounced among
CRT-D recipients.440–442 However, most of studies have shown simi-
lar mortality rates in both genders after ICD implantation.435–442 AF
is common in patients with left ventricular dysfunction; the preva-
lence can increase up to 50%. Worsening AF subtype increases the
risk for both appropriate shocks and overall mortality.443–446
Other risk factors implicated to increase the risk of appropriate
shocks are diabetes,443,447 elevated baseline NT-proBNP and
BNP,448 NSVT,445,449 left atrial diameter,443,449 and impaired renal
function.450 Data from SCD-HeFT and MADIT II trials have found a
higher NYHA class, a lower LVEF, lack of use of beta-blocker therapy
and single-chamber ICD as significant independent predictors for ap-
propriate ICD shocks.451 Data from the Danish ICD Registry showed
that LVEF <25% predicted an increased risks of both appropriate and
inappropriate therapies.452
Inappropriate shock predictors
The presence of supraventricular tachycardias, in particular AF, has
been reported as the most common risk factor for inappropriate
ICD shocks.426,444,445 Another risk factor associated with inappropri-
ate shock is younger age.448,450,451 Inappropriate shocks secondary
to AF/atrial flutter are associated with increased mortality while inap-
propriate shocks related to sinus tachycardia or non-arrhythmic
events like noise, artefact, and oversensing have shown similar sur-
vival as compared to those who do not receive a shock.453 Studies
have failed to establish the superiority of dual-chamber ICD over the
single chamber in reducing inappropriate shocks.454,455 The Danish
ICD Registry showed a two-fold increase in the risk of inappropriate
shocks associated with a dual-chamber ICD.456 Device technologies
and programming, i.e. prolonged detection time, high rate program-
ming, and better discrimination algorithms have markedly reduced
the risk of inappropriate therapies.370,456,457
Risk for heart failure incidence and
progression
Tachycardia-induced cardiomyopathy is a reversible cause of HF and
impaired left ventricular function. Ventricular rhythms causing
tachycardia-induced cardiomyopathy include VT, fascicular tachycar-
dia, PVCs, and even persistent rapid DDD pacing. Left ventricular
systolic function improves or normalizes and symptoms resolve,
when tachycardia is corrected or controlled with medication or
pharmacologic or non-pharmacologic rhythm control strategies.
Sustained monomorphic VT less commonly causes tachycardia-
induced cardiomyopathy as compared to supraventricular tachycar-
dias, since sustained VT is most often associated with some form of
structural heart disease. When VT does lead to tachycardia-induced
cardiomyopathy, it is by definition idiopathic and most commonly
originates from the RVOT, left ventricular outflow tract, or coronary
cusps. If these arrhythmias become persistent or high burden, they
may cause reversible left ventricular dysfunction.467
A single centre series reported that 11% of patients who pre-
sented with frequent PVCs also had sustained monomorphic VT and
7% of those patients had tachycardia-induced cardiomyopathy. The
presence of repetitive monomorphic VT was a significant predictor
of tachycardia-induced cardiomyopathy development, particularly
when it was the predominant arrhythmia on 24-h Holter
monitoring.461
PVCs are very common and usually do not require treatment in
the absence of symptoms. However, in the clinical setting of trouble-
some symptoms, or when PVCs trigger polymorphic VT or cause
cardiomyopathy, proper treatment is critical. The concept of PVC-
induced cardiomyopathy was first proposed by Duffee et al.,460 who
observed a small group of patients with cardiomyopathy recover
normal left ventricular function after pharmacological suppression of
frequent PVCs.
Baman et al.459 reported on 174 consecutive patients referred for
PVC ablation, 54 of whom had depressed left ventricular function.
The authors concluded that although PVC-related cardiomyopathy
may occur in patients with less PVCs, “in the presence of a PVC bur-
den >_24%, it may be helpful to suppress the PVCs by catheter abla-
tion or drug therapy to avoid the development of cardiomyopathy.”
However, Aki Lee et al., demonstrated a high rate of resolution of
.................................................................................................
Risk for heart failure incidence
and progression
Class References
Periodic monitoring of PVC burden (ev-
ery 6 months) and LVEF and dimen-
sions are useful in patients with
frequent, asymptomatic PVCs and a
normal LVEF and dimensions.
458
PVC burden exceeding 20% is associ-
ated with a higher risk of PVC-related
cardiomyopathy.
459–461
PVC burden lower than 10% is associ-
ated with a lower risk of PVC-related
cardiomyopathy.
462,463
In patients with PVC-related cardiomy-
opathy, absence of LGE on cardiac
MRI may be used to identify patients
with a favourable prognosis of left
ventricular systolic function recovery.
464–466
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frequent PVCs among untreated patients with normal left ventricular
function and minimal symptoms. A strategy of active surveillance is
appropriate for the majority of patients with frequent idiopathic
PVCs in association with preserved LVEF, owing to the low risk of de-
veloping left ventricular systolic dysfunction and the high rate of
spontaneous resolution. Periodic monitoring of PVC burden and
LVEF and dimensions can be useful in patients with frequent, asymp-
tomatic PVCs and a normal LVEF and dimensions.458
It has become clear that comparative effectiveness trials are
needed to understand what the best treatment approach is for
patients with frequent PVCs and cardiomyopathy. A pilot multicentre
study (PAPS: Prospective Assessment of PVC Suppression in
Cardiomyopathy) is ongoing to better understand the prevalence of
frequent PVCs and CM, and prove the feasibility of a large-scale ran-
domized clinical trial (not yet published).468
Several circumstances have been associated with PVC-induced
cardiomyopathy, including the PVC burden, asymptomatic status, du-
ration of a high PVC burden, PVC QRS width >150 ms, interpolated
PVCs, epicardial origin, and male gender. However, no prospective
longitudinal assessments have been conducted that definitively prove
their causal relation to PVC-induced cardiomyopathy.469
The diagnosis of tachycardia-induced cardiomyopathy or PVC-
related cardiomyopathy can be challenging and the role of imaging
modalities in the characterization of myocardial tissue as part of the
diagnostic workup is limited.464 Cardiac MRI with LGE can accurately
identify the presence and extent of myocardial scar and has become
a first-line non-invasive imaging modality for the aetiologic assess-
ment of primary cardiomyopathies and/or left ventricular systolic
dysfunction, and could identify early stage of the structural heart
disease.
Risk for death in ventricular
tachyarrhythmia patients
Risk prediction of death in VT patients has used numerous non-
invasive and invasive markers including: clinical markers, mode of
initial clinical presentation (e.g. sustained stable monomorphic VT,
ventricular flutter, or VF), biomarkers, ECG abnormalities (e.g. left
bundle branch block), heart rate variability, signal-averaged ECG, am-
bulatory ECG-based frequency domain T wave, microvolt level-T
wave alternans, heart rate turbulence, heart rate deceleration, QT
dispersion, cardiac autonomic function, echocardiographic evaluation
of LVEF, left ventricular diameter, left ventricular mechanical disper-
sion by tissue Doppler, strain and velocity parameters to evaluate re-
gional LV function, exercise testing to evaluate functional status, MRI
to measure scar burden, and EPS to assess for inducibility of VT.
Most of these tests and markers were applied to patients at risk of
SCD and not patients who already have VT. Thus, their use for pre-
dicting death in a patient with VT is unknown.
The main sources of information about risk for SCD in patients
with VT are from two studies from the era prior to widespread ICD
use,475,476 the control groups (patients who did not receive ICDs) in
the primary prevention ICD studies (MUSTT, MADIT, MADIT II,
SCD-HeFT, DANISH, DEFINITE, CABage-PATCH, IRIS, DINAMIT)
as well as analysis of large data samples from registries since ICD ap-
proval from Europe, Canada, and the USA.70,477 These data have
been extensively reviewed to better characterize which variables
predict the development of SCD and death in high-risk patients. Data
from secondary prevention studies (AVID, CIDS, CASH) provide ad-
ditional information about risk of death in patients who have had VT.
Another source of information is the International VT Ablation
Center Collaborative Study Group which analysed a large group of
patients with VT (approximately 2000 patients from 12 international
sites) undergoing catheter ablation.478 Finally, a third useful source of
data is the Seattle Heart Failure model developed by Wayne Levy
and his colleagues who analysed data from a large sample of heart fail-
ure patients to predict risk of death and SCD as well as create a
model for predicting benefit from ICD therapy.479 This model has
been prospectively validated among five additional study cohorts of
almost 10 000 heart failure patients. It is important to recognize that
the causes of death can change over time. For example, the risk of
death in a patient with post-MI VT may be largely due to mechanical
problems (VSD, mitral regurgitation, heart failure) in the first several
weeks to months after MI and then 3–6 months later the risk of ar-
rhythmic death may be much higher due to matured scar-mediated
substrate.
Based on these studies, the risk factors for death in VT patients in-
clude increasing NYHA class, old age, female gender, electrical storm,
frailty, diabetes mellitus, AF, chronic kidney disease, chronic obstruc-
tive lung disease, peripheral arterial disease, advanced HF, non-ICM,
lower EF, multiple different VT morphologies, use of haemodynamic
support devices during VT ablation, and poor functional status. These
risk factors can be divided into risk factors related to non-cardiac dis-
ease (e.g. renal function, diabetes, COPD, peripheral arterial disease)
which are powerful and determine mortality, and cardiac risk factors
(ischaemic vs. non-ischaemic aetiology, multiple morphologies of VT,
EF, and functional status). There was an interaction between varia-
bles, such as higher rates of both VT recurrence and mortality, which
was observed in patients with lower EF and worse NYHA failure
status.478,479
.................................................................................................
Risk for death in VT patients (in-
cluding risk for SCD)
Class References
Risk for SCD should be judged in each
patient on a case-by-case basis and
risk considered as a continuous vari-
able rather than a dichotomized vari-
able (high or low risk may change).
71,470,471
Individual risk assessment needs to be
dynamic as the type and severity of
risks can change over time (repeated
measurements need to be made over
time).
472
Risk assessment may include consider-
ation of mode of death as the relative
risk of non-sudden, non-cardiac
death, sudden cardiac death, and non-
sudden cardiac death is influenced by
aging and worsening cardiomyopathy
and cardiovascular risk factors.
369,473,474
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Risk of adverse outcomes in patients
treated with catheter ablation
Risk of death or acute haemodynamic compromise in patients who
undergo catheter ablation of ventricular arrhythmias is driven by pa-
tient-specific factors (comorbidities), procedural factors, and presen-
tation of the patient. In a large retrospective multicentre registry,
factors such as low EF, chronic kidney disease, VT storm, and unmap-
pable VTs were associated with early mortality.484 As mentioned
above, male sex is associated with occurrence of VT/VF and ICD
shocks.485 As procedural factors are often difficult to determine prior
to the procedure, various risk scores have been developed to assess
risk of acute haemodynamic compromise and/or death in patients un-
dergoing catheter ablation of VT. Of these, a modified version of the
Seattle HF Model and PAINESD score have been used in single cen-
tre and multicentre retrospective studies to evaluate risk of acute
haemodynamic compromise or death post-procedure.481,482,484 The
Seattle HF Model incorporates, amongst other variables, age, EF,
blood pressure, weight, gender, HF medications, blood electrolyte,
and haemoglobin levels as well as NYHA to predict mortality. A
modified version of this model which incorporates VT storm and
ICD shocks was recently reported to be potentially more useful in
predicting 6 months survival in patients who undergo VT ablation.483
The PAINESD score incorporates pulmonary disease, age, presence
of ICM, NYHA, EF, VT storm, and diabetes and assigns a score be-
tween 3 and 6 to each of these patient characteristics. In retrospec-
tive studies, patients with a PAINESD score greater than 15 had a
24% risk of acute haemodynamic compromise and a significantly
higher risk of mortality.482,484 Use of these risk scores can be impor-
tant in discussion of risks and benefits in patients undergoing catheter
ablation and may help determine need for haemodynamic support
during the procedure. However, larger multicentre prospective stud-
ies are required. It is important to note that patients with lower EF
and NYHA Class IV HF may still benefit from successful catheter ab-
lation of VT, and freedom from VT after successful ablation is associ-
ated with improved mortality.478,486
With regard to VT recurrence, in addition to patient related
comorbidities, large single centre and multicentre studies have shown
that the risk of VT recurrence is driven by the underlying aetiology,
particularly in patients with non-ischaemic heart disease, even after
adjusting for other patient comorbidities.487–489 In particular, patients
with Lamin A/C cardiomyopathy, hypertrophic cardiomyopathy, car-
diac sarcoidosis, and valvular cardiomyopathy appear to be at higher
risk for VT recurrence after catheter ablation as compared to idio-
pathic DCM.480,487 In addition, location of scar seems to determine
risk of VT recurrence post-catheter ablation.490 In this regard, endo-
cardial ablation alone may be insufficient in many non-ischaemic car-
diomyopathies. In arrhythmogenic right ventricular cardiomyopathy,
epicardial presence of scar can serve as the substrate for VT and
combined endo-epicardal mapping and ablation or adjuvant epicardial
ablation after endocardial ablation is often required.491–494 Cardiac
MRI with LGE can be used in assessment of scar location and may be
beneficial in diagnosis and peri-procedural planning of VT ablation.495
Retrospective studies have shown that inducibility of VT at the end
of ablation is associated with adverse outcomes, even after adjusting
for other patient comorbidities. Non-inducibility of VT in ICM
patients was shown to be associated with improved arrhythmia-free
survival rates and all-cause mortality,496,497 even after adjusting for
other comorbidities. In addition, inducible clinical VT during non-
invasive programmed electrical ventricular stimulation (PES) is associ-
ated with decreased 1-year VT free survival as compared with those
who are not inducible (<30% vs. >80%)498
Patients who were non-inducible during non-invasive PES after ab-
lation had a VT recurrence rate of only 9% at 1 year of follow-up
when both acute (at the end of the procedure) and late (at 6 days
post-procedure) programmed stimulation were negative.499
Therefore, PES may be used to guide redo ablation and address ICD
programming.
Finally, although catheter ablation is generally performed after the
occurrence of ICD therapies, two clinical trials reported the value of
catheter ablation prior to or in conjunction with ICD implantation.
The Prophylactic Catheter Ablation for Prevention of Defibrillator
Therapy clinical trial randomized patients with spontaneous ventricu-
lar tachycardia or fibrillation and history of myocardial infarction to
ICD or ICD and catheter ablation. In this trial, 30-day mortality was
zero along with a significant reduction in ICD therapies from 31% to
9% between the control (ICD) and intervention arms (ICDþ cathe-
ter ablation).500 The Catheter Ablation of Stable Ventricular
Tachycardia before Defibrillator Implantation in Patients with
Coronary Heart Disease (VTACH) trial randomized patients with
history of myocardial infarction and stable VT to catheter ablation
followed by ICD implantation vs. ICD implantation alone and showed
that catheter ablation reduced occurrence of VT or VF by 18% at
2 years of follow-up. These data imply that in patients who receive
ICD for secondary prevention and have ischaemic heart disease,
catheter ablation can be considered earlier, at the time of ICD im-
plantation, to reduce future ICD therapies and prior to potential pre-
sentation with VT storm.501 The impact of early ablation (at the time
of ICD implantation) on mortality was the subject of the BERLIN-VT
clinical trial, early results of which have indicated a lack of a difference
in death or hospitalization for VT/VF in the deferred group (ablation
after occurrence of third appropriate shock) vs. those who under-
went prophylactic ablation at the time of ICD implantation.502 It is
.................................................................................................
Risk of adverse outcomes in
patients treated with catheter
ablation
Class References
The aetiology and severity of cardio-
myopathy and inducibility of
arrhythmias after VT ablation are
useful in determining risk of re-
currence of VT after catheter
ablation.
480
Risk scores in combination with pro-
cedural characteristics may be
useful for assessing adverse out-
comes associated with catheter
ablation of VT.
481–483
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important to note that in these studies, patients had a history of VT
or VF. In patients with ischaemic heart disease undergoing ICD im-
plantation for primary prevention of sudden cardiac death, prophy-
lactic substrate modification of scar by catheter ablation requires
further investigation. In the Substrate Modification Study, patients
randomized to ICD implantation plus VT ablation had similar time to
VT recurrence as those who underwent ICD implantation only.
However, catheter ablation at the time of ICD implantation was asso-
ciated with a greater than 50% reduction in total number of ICD ther-
apies throughout the follow-up period.503
How to assess risk for adverse
outcome in patients with other
specific cardiac conditions
Patients with ventricular premature
contractions
Frequent PVCs can lead to cardiomyopathy and HF, and are associ-
ated with increased mortality.504 In addition, in some patients with an
inherited ACM, PVCs may be the initial clinical manifestation that
leads to this diagnosis. An initial case series describing four patients
who had reversal of cardiomyopathy after amiodarone successfully
suppressed a high PVC burden has resulted in the recognition for the
potential reversibility of this condition.460 However, only a minority
of patients with PVCs will develop symptoms or adverse sequelae.
The factors that can potentially predict development of HF and in-
creased risk of adverse outcomes include PVC frequency as well as
characteristics of the PVC morphology and timing of the PVC cou-
pling interval.
Premature ventricular complex frequency
In a large cohort of patients, increased PVC frequency was associated
with reduced LV function, a higher incidence of heart failure, and a
higher risk of death. Specifically, compared to the lowest quartile of
PVC frequency (<0.002%), the highest quartile (0.123% to 17.7%) in
this cohort of patients with a structurally normal heart at baseline
had a 31% increased risk of death over a follow-up of >13 years.504
Other studies correlating frequency with PVC-induced cardiomyopa-
thy suggested a threshold effect observed at >20%, though there is
no accepted cut-off that appears to be protective.459,505 In a study of
239 consecutive patients with apparently normal hearts, a PVC bur-
den of >20 000 in 24 h was associated with a reduced LVEF, whereas
>10 000 but <20 000 showed LV dilation with preserved LVEF.507
Premature ventricular complex morphology
In addition to PVC burden, the morphological features of the PVC
have been evaluated. The width of the PVC QRS complex, perhaps
reflective of dyssynchrony, has been associated with increased risk of
developing PVC-induced cardiomyopathy.505,506 In these retrospec-
tive studies, patients with a PVC duration of >150 ms appeared to re-
quire a lower burden for development of a cardiomyopathy. A PVC
duration of >153 ms in patients with a > 10% burden, was associated
with an 82% sensitivity and 75% specificity for subsequent develop-
ment of a cardiomyopathy. The presence of multiform PVCs has also
been associated with the development of new onset heart failure.508
Premature ventricular complex coupling interval
One mechanism of PVC-induced cardiomyopathy may be due to in-
effective mechanical contraction leading to adverse remodelling, pos-
sibly related to the timing of the PVC. However, there are only a few
small studies evaluating this. In a retrospective cohort study of 510
patients, a PVC coupling interval of <450 ms was associated with a re-
duced LVEF.509 Another smaller study of 70 patients did not show
any association, though its power was limited.510 Another study spe-
cifically identified the presence of interpolated PVCs regardless of
coupling interval as associated with reduced LVEF.511 A short PVC
coupling interval may also be an important determinant of VF, espe-
cially in patients with genetic or acquired early or abnormal
repolarization.42,512,513
While the promise of effective treatment for reversing the poten-
tial adverse cardiac effects of frequent PVCs remains a possibility, it
remains unclear whether such patients can easily be identified. Most
cardiologists accept the dose–response relationship of PVC burden
and reduced cardiac function, although the precise threshold for this
effect remains unknown. There also is the potential for other factors
aside from frequency alone, such as PVC QRS duration and coupling
intervals, to influence adverse events associated with frequent PVCs.
Patients with supraventricular
tachyarrhythmia such as Wolff–
Parkinson–White syndrome and focal
atrial tachycardia
Patients with WPW may experience dramatic adverse events includ-
ing SCD due to VF.516 The estimate for the frequency of SCD ranges
up to 4% with more recent studies reporting a rate of 2%.514
Alarmingly, in approximately half of the patients SCD is the first clini-
cal manifestation of the syndrome rendering appropriate risk stratifi-
cation essential.515
.................................................................................................
Patients with ventricular prema-
ture contractions
Class References
An evaluation of cardiac function and
screening for heart failure symptoms
should be considered in patients with
frequent ventricular ectopy (>10 000
PVCs within 24 h or >10% over a
more extended timeframe).
504
An evaluation of cardiac function and
screening for heart failure symptoms
may be considered in patients with
frequent multiform PVCs, PVCs with
a QRS duration > 150 ms or PVCs
with a coupling interval of <450 ms.
505,506
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Risk assessment strategies have been recently reviewed in the
2019 ESC Guidelines for the management of patients with supraven-
tricular tachycardia.520 Main risk factors for the development of ma-
lignant arrhythmias and SCD in patients with pre-excitation are: (i) a
short anterograde refractory period of the accessory pathway with
the optimal cut-off reported to be at 250 ms and (ii) inducible atrio-
ventricular reentrant tachycardia triggering pre-excited AF. A short
pre-excited RR interval during AF <_ 250 ms and the presence of mul-
tiple accessory pathways have been also reported as risk markers.
For these reasons, EPS is recommended for risk stratification in sub-
jects with asymptomatic ventricular pre-excitation who either have
high-risk occupations or are competitive athletes. In patients without
high-risk occupations or those who are not competitive athletes, EPS
should be considered for risk stratification of patients with
asymptomatic pre-excitation that can derive a prognostic benefit
from prophylactic catheter ablation of the accessory pathway.520
Permanent Junctional Reciprocating Tachycardia (PJRT) re-presents
a rare form of atrioventricular reciprocating tachycardia using a con-
cealed accessory pathway. The incessant behaviour of PJRT may re-
sult in tachycardia-induced cardiomyopathy that usually resolves
after successful treatment by RF catheter ablation.
Non-invasive testing may also be helpful. Non-invasive findings
that identify a pathway not capable of maintaining rapid conduction
during AF include intermittent loss of conduction over the accessory
pathway on the resting ECG or during ambulatory monitoring, and
abrupt loss of pre-excitation during exercise testing.518,519
Focal atrial tachycardias are characterized by regular atrial activa-
tion from atrial areas with centrifugal spread and can be classified as
sustained or non-sustained. Sustained focal atria tachycardia in the
adult population is usually associated with a benign prognosis, al-
though tachycardia-mediated cardiomyopathy has been reported in
up to 10% of patients referred for ablation of incessant SVT.521 Non-
sustained atrial tachycardia is frequently found on Holter recordings
and often does not require treatment; however, we should consider
that patients with a high premature atrial complex burden (>500/
24 h) are at increased risk for developing of AF and be educated on
the symptoms of AF.522
Summary
In clinical practice and for scientific purposes, cardiologists and pri-
mary care physicians perform risk assessment in patients with cardiac
diseases or conditions with high risk of developing such.
The European Heart Rhythm Association (EHRA), Heart Rhythm
Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the
Latin American Heart Rhythm Society (LAHRS) set down this expert
consensus statement task force to summarize the consensus regard-
ing risk assessment in cardiac arrhythmias. Objectives were to raise
awareness of using the right risk assessment tool for a given outcome
in a given population, and to provide physicians with practical pro-
posals that may lead to rational and evidence-based risk assessment
and improvement of patient care in this regard. A large variety of
methods are used for risk assessment and choosing the best methods
and tools hereof in a given situation is not simple. Even though param-
eters and test results found associated with increased risk of one out-
come (e.g. death) may also be associated with higher risk of other
adverse outcomes, specific risk assessment strategies should be used
only for the purposes for which they are validated.
The work of this task force is summarized in a row of consensus
statement tables.
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Patients with supraventricular
tachyarrhythmia such as WPW
syndrome and focal atrial
tachycardia
Class References
EPS, with the use of isoprenaline, is rec-
ommended to risk stratify individuals
with asymptomatic pre-excitation
who have high-risk occupations/hob-
bies, and those who participate in
competitive athletics.
514–516
EPS should be considered for risk strati-
fication in asymptomatic pre-excita-
tion patients without high-risk
occupations or those who are not
competitive athletes.
514,516,517
Non-invasive screening with exercise
testing, drug testing, and ambulatory
monitoring may be considered for
risk stratification in asymptomatic
pre-excitation patients without high-
risk occupations or those who are
not competitive athletes.
514,516,517
High-risk features to consider at EPS
with or without catecholamine chal-
lenge are accessory pathways with an
antegrade refractory period <_250 ms,
shortest pre-excited RR interval dur-
ing AF <_250 ms, inducible atrioven-
tricular re-entrant tachycardia, and
multiple accessory pathways.
514,518,519
Observation without treatment may be
reasonable in asymptomatic WPW
patients who are considered to be at
low risk following EPS, abrupt loss of
pre-excitation during exercise testing,
or due to intermittent pre-excitation
on a resting ECG or during ambula-
tory monitoring.
514,516
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Incidence of complications related to catheter ablation of atrial fibrillation and
atrial flutter: a nationwide in-hospital analysis of administrative data for
Germany in 2014. Eur Heart J 2018;39:4020–9.
324. Fink T, Metzner A, Willems S, Eckardt L, Ince H, Brachmann J et al. Procedural
success, safety and patients satisfaction after second ablation of atrial fibrillation
in the elderly: results from the German Ablation Registry. Clin Res Cardiol 2019;
108:1354–63.
325. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ et al. Long-
term natural history of adult Wolff-Parkinson-White syndrome patients treated
with and without catheter ablation. Circ Arrhythm Electrophysiol 2015;8:1465–71.
326. Haissaguerre M, Jaı̈s P, Shah DC, Takahashi A, Hocini M, Quiniou G et al.
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pul-
monary veins. N Engl J Med 1998;339:659–66.
327. Ebert M, Stegmann C, Kosiuk J, Dinov B, Richter S, Arya A et al. Predictors,
management, and outcome of cardioversion failure early after atrial fibrillation
ablation. Europace 2018;20:1428–34.
328. Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GY. Clinical scores for
outcomes of rhythm control or arrhythmia progression in patients with atrial fi-
brillation: a systematic review. Clin Res Cardiol 2017;106:813–23.
329. Degiovanni A, Boggio E, Prenna E, Sartori C, De Vecchi F, Marino PN; From
the Novara Atrial Fibrillation (NAIF) Study Group. Association between left
atrial phasic conduit function and early atrial fibrillation recurrence in patients
undergoing electrical cardioversion. Clin Res Cardiol 2018;107:329–37.
330. Mujovic N, Marinkovic M, Lip GY, Potpara TS. Predicting recurrent atrial fibrilla-
tion after catheter ablation. Europace 2018;20:f460–f461.
331. Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D,
Bollmann A et al. Is epicardial fat tissue associated with atrial fibrillation recur-
rence after ablation? A systematic review and meta-analysis. Int J Cardiol Heart
Vasc 2019;22:132–8.
332. Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H
et al. Development and validation of a risk score for predicting atrial fibrillation
recurrence after a first catheter ablation procedure—ATLAS score. Europace
2018;20:f428–35.
333. Winkle RA, Jarman JW, Mead RH, Engel G, Kong MH, Fleming W et al.
Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart
Rhythm 2016;13:2119–25.
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